var title_f18_42_19104="Malignant perivascular nodules";
var content_f18_42_19104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perivascular nodules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple small perivascular nodules, due to metastatic small cell carcinoma, are scattered diffusely throughout all compartments of the lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19104=[""].join("\n");
var outline_f18_42_19104=null;
var title_f18_42_19105="Choledochoscope for lithotripsy";
var content_f18_42_19105=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Choledochoscope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A choledochoscope can be introduced via the working channel of a therapeutic side-viewing duodenoscope for retrograde access to the biliary system. The system can be worked by one endoscopist and one endoscopy nurse.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lingenfelser, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19105=[""].join("\n");
var outline_f18_42_19105=null;
var title_f18_42_19106="TEE contrast atrial septal defect";
var content_f18_42_19106=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1088px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/61938/teeasdwc_conv.mp4?title=TEE+contrast+atrial+septal+defect\" style=\"width:383px;height:276px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiography with contrast of a large atrial septal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast is seen filling the right atrium (RA) in systole and an atrial septal defect (ASD) can be seen. During diastole a large amount of contrast (red arrow) passes from the RA to the left atrium through the ASD as a result of right to left shunting of blood.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19106=[""].join("\n");
var outline_f18_42_19106=null;
var title_f18_42_19107="Patient information: Choosing between dialysis and kidney transplant (The Basics)";
var content_f18_42_19107=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16438\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"         Anatomy of the urinary tract",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/59/37809\">",
"          Kidney transplant",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/22/25952\">",
"           Peritoneal dialysis",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/5/93\">",
"            Hemodialysis",
"           </a>",
"           <li>",
"            <a class=\"graphic graphic_table\" href=\"UTD.htm?23/34/24108\">",
"             The benefits and downsides of kidney transplant, peritoneal dialysis, and hemodialysis",
"            </a>",
"           </li>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/35/28212\">",
"         Patient information: Chronic kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/2/18467\">",
"         Patient information: Dialysis and diet (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/1/25619\">",
"         Patient information: Hemodialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/46/25315\">",
"         Patient information: Kidney transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?15/43/16051\">",
"         Patient information: Peritoneal dialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?12/15/12531\">",
"         Patient information: Planning for a kidney transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/22/11619\">",
"         Patient information: Preparing for hemodialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/5/13398\">",
"         Patient information: Chronic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/26/9635\">",
"         Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/57/40852\">",
"         Patient information: Hemodialysis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/10/14501\">",
"         Patient information: Peritoneal dialysis (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Choosing between dialysis and kidney transplant (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/choosing-between-dialysis-and-kidney-transplant-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H15947827\">",
"      <span class=\"h1\">",
"       What is renal replacement therapy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Renal replacement therapy is another term for the different treatments for kidney failure.",
"     </p>",
"     <p>",
"      Normally, the kidneys filter the blood and remove waste and excess salt and water (",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"       figure 1",
"      </a>",
"      ). Kidney failure, also called &ldquo;end-stage renal disease,&rdquo; is when the kidneys stop working completely.",
"     </p>",
"     <p>",
"      If the kidneys stop working completely, people can choose between 3 different treatments to take over the job of the kidneys.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15947842\">",
"      <span class=\"h1\">",
"       What are my choices for renal replacement therapy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can choose between:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Kidney transplant &ndash; A kidney transplant is surgery in which a doctor puts a healthy kidney in a person whose kidneys are diseased (",
"        <a class=\"graphic graphic_figure graphicRef59957 \" href=\"UTD.htm?36/59/37809\">",
"         figure 2",
"        </a>",
"        ). The healthy new kidney can then do the job of the diseased kidneys. (People need only 1 kidney to live).",
"        <br/>",
"        <br/>",
"        A new kidney can come from a living donor (usually a family member or friend) or a dead donor. After a kidney transplant, people need to take medicines for the rest of their life to keep their body from reacting badly to the new kidney.",
"        <br/>",
"        <br/>",
"        More information about a kidney transplant can be found in these articles: (See",
"        <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=see_link\">",
"         \"Patient information: Planning for a kidney transplant (The Basics)\"",
"        </a>",
"        and",
"        <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=see_link\">",
"         \"Patient information: Kidney transplant (The Basics)\"",
"        </a>",
"        .)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Peritoneal dialysis &ndash; Peritoneal dialysis is a procedure that people do at home every day. It involves piping a special fluid into the belly. This fluid collects waste and excess salt and water from the blood. Then the used fluid drains out of the belly (",
"        <a class=\"graphic graphic_figure graphicRef71539 \" href=\"UTD.htm?25/22/25952\">",
"         figure 3",
"        </a>",
"        ). Before people can have peritoneal dialysis, they need surgery to have a tube put in their belly. The tube allows the fluid to get in and out of the belly.",
"        <br/>",
"        <br/>",
"        More information about peritoneal dialysis can be found in this article: (See",
"        <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=see_link\">",
"         \"Patient information: Peritoneal dialysis (The Basics)\"",
"        </a>",
"        .)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hemodialysis &ndash; Hemodialysis is a procedure in which a dialysis machine takes over the job of the kidneys. The machine pumps blood out of the body, filters it, and returns it to the body (",
"        <a class=\"graphic graphic_figure graphicRef56992 \" href=\"UTD.htm?0/5/93\">",
"         figure 4",
"        </a>",
"        ). Before people can have hemodialysis, they need surgery to create an &ldquo;access.&rdquo; An access is a way for the blood to leave and return to the body.",
"        <br/>",
"        <br/>",
"        People have hemodialysis at least 3 times a week. Most people can choose between having hemodialysis at a dialysis center (in a hospital or clinic) or at home.",
"        <br/>",
"        <br/>",
"        More information about hemodialysis can be found in these articles: (See",
"        <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=see_link\">",
"         \"Patient information: Preparing for hemodialysis (The Basics)\"",
"        </a>",
"        and",
"        <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=see_link\">",
"         \"Patient information: Hemodialysis (The Basics)\"",
"        </a>",
"        .)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15947857\">",
"      <span class=\"h1\">",
"       What are the benefits and downsides of the different treatments?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The following table lists the benefits and downsides of a kidney transplant, peritoneal dialysis, and hemodialysis (",
"      <a class=\"graphic graphic_table graphicRef75453 \" href=\"UTD.htm?23/34/24108\">",
"       table 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15947872\">",
"      <span class=\"h1\">",
"       How do I choose between the different treatment options?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You, your doctor, and your family will need to work together to find the treatment that&rsquo;s right for you. It will depend partly on your condition, overall health, and home situation. Your doctor can explain all of your options.",
"     </p>",
"     <p>",
"      People usually benefit most from a kidney transplant. But a new kidney is not always available. Plus, not everyone who wants a kidney transplant can get one. People need to meet certain conditions to be able to get a kidney transplant.",
"     </p>",
"     <p>",
"      When thinking about your choices, you should also know that:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        If you are on a list to get a kidney from a dead donor, you might need to wait a long time. You will most likely need to start peritoneal dialysis or hemodialysis while you wait.",
"       </li>",
"       <li>",
"        If you start 1 type of dialysis and it doesn&rsquo;t work for you, you can switch to the other type of dialysis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15947887\">",
"      <span class=\"h1\">",
"       Can I choose not to have any of these treatments?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, you can choose not to have any renal replacement therapy. People usually live for days to weeks without treatment, depending on their kidneys, symptoms, and overall health.",
"     </p>",
"     <p>",
"      If you don&rsquo;t have renal replacement therapy, waste will build up in your blood. This can make you feel tired, itchy, or sick to your stomach. Fluid will also build up in your body. This can cause swelling and trouble breathing. During this time, your doctor will give you medicines to treat your symptoms and make you more comfortable.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15947902\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=see_link\">",
"       Patient information: Kidney transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=see_link\">",
"       Patient information: Planning for a kidney transplant (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=see_link\">",
"       Patient information: Peritoneal dialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=see_link\">",
"       Patient information: Preparing for hemodialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=see_link\">",
"       Patient information: Hemodialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/2/18467?source=see_link\">",
"       Patient information: Dialysis and diet (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"       Patient information: Chronic kidney disease (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"       Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=see_link\">",
"       Patient information: Peritoneal dialysis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       Patient information: Hemodialysis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"       Patient information: Chronic kidney disease (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/42/19107?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16438 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-113.53.254.124-8E465FEC82-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19107=[""].join("\n");
var outline_f18_42_19107=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15947827\">",
"      What is renal replacement therapy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15947842\">",
"      What are my choices for renal replacement therapy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15947857\">",
"      What are the benefits and downsides of the different treatments?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15947872\">",
"      How do I choose between the different treatment options?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15947887\">",
"      Can I choose not to have any of these treatments?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15947902\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16438\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"      Anatomy of the urinary tract",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/59/37809\">",
"       Kidney transplant",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/22/25952\">",
"        Peritoneal dialysis",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/5/93\">",
"         Hemodialysis",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_table\" href=\"UTD.htm?23/34/24108\">",
"          The benefits and downsides of kidney transplant, peritoneal dialysis, and hemodialysis",
"         </a>",
"        </li>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=related_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/2/18467?source=related_link\">",
"      Patient information: Dialysis and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/1/25619?source=related_link\">",
"      Patient information: Hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=related_link\">",
"      Patient information: Kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/10/14501?source=related_link\">",
"      Patient information: Peritoneal dialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/43/16051?source=related_link\">",
"      Patient information: Peritoneal dialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=related_link\">",
"      Patient information: Planning for a kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/22/11619?source=related_link\">",
"      Patient information: Preparing for hemodialysis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_42_19108="Severe cystic acne PI";
var content_f18_42_19108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F54107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F54107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe cystic acne",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient was subsequently treated with isotretinoin (Accutane).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19108=[""].join("\n");
var outline_f18_42_19108=null;
var title_f18_42_19109="Pseudoporphyria";
var content_f18_42_19109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pseudoporphyria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vesiculation and crusting are present on the dorsal hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:",
"     <a href=\"file://www.visualdx.com\" target=\"_blank\">",
"      www.visualdx.com",
"     </a>",
"     . Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19109=[""].join("\n");
var outline_f18_42_19109=null;
var title_f18_42_19110="Rheumatoid pleural disease chest x-ray";
var content_f18_42_19110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74857%7EPULM%2F63153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74857%7EPULM%2F63153&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rheumatoid pleural disease chest x-ray",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 313px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Loculated right pleural effusion in a patient with rheumatoid arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rheumatoid pleural disease CT scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography demonstrates extensive thickening of the visceral pleura in a patient with rheumatoid arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19110=[""].join("\n");
var outline_f18_42_19110=null;
var title_f18_42_19111="Compliance with lipid altering medications and recommended lifestyle changes";
var content_f18_42_19111=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Compliance with lipid altering medications and recommended lifestyle changes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/42/19111/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/42/19111/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/42/19111/contributors\">",
"     Lynne T Braun, PhD, RN, CNP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/42/19111/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/42/19111/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/42/19111/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/42/19111/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/42/19111/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/42/19111/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonadherence to evidence-based pharmacotherapy is associated with excess morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The importance of compliance with lipid-altering medications in patients with dyslipidemia was demonstrated in a post-hoc analysis of data from the West of Scotland Coronary Prevention Study (WOSCOPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/3\">",
"     3",
"    </a>",
"    ]. In this primary prevention study of men with hypercholesterolemia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    therapy was shown to decrease cardiovascular morbidity and mortality (",
"    <a class=\"graphic graphic_figure graphicRef59494 \" href=\"UTD.htm?21/5/21598\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mean adherence for the entire group was 70 percent. Those patients in the treatment group with more than 75 percent adherence had the following benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fewer definite coronary events (risk reduction of 38 versus 31 percent compared with patients treated with placebo)",
"     </li>",
"     <li>",
"      Lower cardiovascular mortality (risk reduction of 37 versus 32 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This dose-response effect associated with better adherence argues for improving medication adherence to maximize therapeutic response. Other benefits of adherence to drug therapy may include decreased utilization of medical services, better quality of life, and reduced social costs such as lost productivity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, since the risk factors for coronary heart disease (eg, lipid abnormalities, smoking, sedentary lifestyle, hypertension, diabetes mellitus) tend to be additive, nonadherence to medical or behavioral treatment of any individual risk factor results in a higher level of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Furthermore, nonadherence to one part of the medical regimen may increase the likelihood of nonadherence to other components.",
"   </p>",
"   <p>",
"    The American Heart Association expert panel on compliance has reviewed existing adherence-enhancing strategies found effective in clinical research and has made recommendations involving patient education, contracts, self monitoring, tailoring interventions to individual needs, telephone follow-ups, and social support [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/7\">",
"     7",
"    </a>",
"    ]. Strategies likely to be effective to address patient nonadherence to lipid altering therapy and lifestyle change recommendations are reviewed here. A discussion of the data concerning the effectiveness of lipid altering medication is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL FACTORS AFFECTING TREATMENT ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous patient-related factors that are not specific to the type of treatment can affect adherence to treatment regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Memory or concentration problems, or loss of capacity to understand the impact of treatment versus no treatment may have a substantial impact or be relatively subtle following stroke, myocardial infarction, hypoxia, surgery, and other disorders or procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Psychopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical depression (found in 18 to 44 percent of cardiac patients over the course of their disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/8\">",
"     8",
"    </a>",
"    ]) influences a patient's energy to make and sustain changes, increases hopelessness, and promotes thoughts that treatment does not matter. Anxiety may be associated with the negative interpretation of side effects and greater somatic sensitivity to symptoms and side effects, both of which may lead to avoidance of medical treatment and caregivers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. A high level of anger and hostility is four times as likely in heart transplant patients with persistent medication compliance problems [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Motivation for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Feeling pressured by others and conflicted about change is associated with nonadherence; by comparison, intrinsically motivating reasons which involve positive self-related outcomes help sustain adherence (eg, \"I want to stay healthy to see my grandchildren grow up\") [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/12\">",
"     12",
"    </a>",
"    ]. Fear tends to promote initial but not sustained adherence, and also can lead to denial and fatalism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Functional illiteracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional health illiteracy is common in some patient groups. In one study, 41 percent of patients age 60 and older did not understand the phrase \"take on an empty stomach\"; 50 percent of their spouses and 25 percent of their children were unaware of the patient having this difficulty [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17609?source=see_link\">",
"     \"Literacy and patient care\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Interactions with clinicians",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improved adherence may result from using nontechnical language, providing precise information about the effects of treatment and side effects, and collaborating on a treatment plan which incorporates the patient's motivations and difficulties with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Lack of clinical follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lack of clinical follow-up may adversely affect adherence and treatment outcomes. These can be substantially improved using a case management approach in which follow-up phone calls to deal with adherence problems are made by nurses or other allied caregivers. In a study of 585 patients hospitalized for an acute myocardial infarction and randomized to a case management intervention with frequent follow-up or usual medical care, the case management approach resulted in the following benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased smoking cessation rate at two month follow-up (70 versus 50 percent, p = 0.03)",
"     </li>",
"     <li>",
"      Decreased plasma LDL cholesterol levels at two months (107 versus 132",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.77 versus 3.41",
"      <span class=\"nowrap\">",
"       mmol/L],",
"      </span>",
"      p = 0.001)",
"     </li>",
"     <li>",
"      Improved functional capacity at six months (9.3 versus 8.4 METS, p = 0.001)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SPECIFIC FACTORS AFFECTING ADHERENCE TO LIPID-ALTERING MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prescribed medications may be refused or taken in other than the prescribed regimen for a variety of reasons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Side effects of medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid-altering agents have a wide range of side effects. As examples, HMG CoA reductase inhibitors generally have few side effects, while the side effects of bile acid sequestrants (nausea, bloating, and cramping) and nicotinic acid (flushing, pruritus, paresthesias, and nausea) are obvious and unpleasant to patients, and likely to reduce adherence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Complexity and organization of regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex regimens involving many medications taken at different times are associated with poor adherence. As an example, a cohort study found that nonadherence to statins and angiotensin converting enzyme inhibitors or angiotensin receptor blockers increased with the complexity of the treatment regimen and prescription filling as measured by numbers of prescribed medications, prescribers, pharmacies, pharmacy visits, and pharmacy visits per prescription fill [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Simplified regimens or the use of charts or pill organizers can improve adherence, as can involving spouses, other family members, or home nursing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cost, inconvenience, and lifestyle barriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Financial cost is a barrier for many patients. The inconvenience of changing a daily routine to incorporate medications, or the maintenance of a medication schedule while traveling, camping, or on vacation may affect adherence. A study found that obtaining statins through a mail-order pharmacy rather than a local pharmacy was associated with improved control of LDL-cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/19\">",
"     19",
"    </a>",
"    ]. Medications also often require lifestyle changes (eg, in alcohol consumption and diet) that may be difficult to implement or maintain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Health beliefs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health beliefs are particularly important in medication adherence (",
"    <a class=\"graphic graphic_table graphicRef82636 \" href=\"UTD.htm?7/42/7851\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk perceptions concerning illness &mdash; The perceived threat of cardiovascular disease is often minimized by patients (eg, patients in their 30s or 40s who believe they are not susceptible to an \"old person's\" disease).",
"     </li>",
"     <li>",
"      Perceived benefits of treatment &mdash; Clear communication of progress (changes in lipid values and their meaning to the patient) is essential. The lack of perceived symptoms in lipid disorders means that the patient's understanding of the benefits of treatment and his or her motivation to continue is based upon the effectiveness of communication with the medical team.",
"     </li>",
"     <li>",
"      Barrier beliefs concerning medicines or a specific medicine &mdash; Patients often are concerned about medication interactions or taking too many medications (eg, \"When I have to take so many medications, I feel old\"). They also frequently have misinformation or misunderstandings about treatment (eg, \"When my labs are normal, I can quit treatment\"). Personal beliefs about \"becoming dependent\" upon medicine or preferences for lifestyle changes or alternative approaches to healthcare also frequently affect medication adherence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SPECIFIC FACTORS AFFECTING ADHERENCE TO LIFESTYLE RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above problems, additional factors affect adherence to lifestyle changes. Patients typically are more resistant to both remembering and following through on lifestyle recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/15,22\">",
"     15,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Stage of change",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's stage of change (their readiness to adopt a change in lifestyle) is a more important consideration for lifestyle recommendations than when medications are prescribed. The discussion which follows is based upon the Stages of Change Model [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Effective physician intervention differs at each stage (",
"    <a class=\"graphic graphic_table graphicRef65493 \" href=\"UTD.htm?15/53/16219\">",
"     table 2",
"    </a>",
"    ). In assessing stage of change, the question for the clinician is whether the patient is ready to adopt the recommended lifestyle change.",
"   </p>",
"   <p>",
"    If not, is the patient:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Not thinking about it at all (precontemplation stage)",
"     </li>",
"     <li>",
"      Thinking about it (contemplation stage)",
"     </li>",
"     <li>",
"      Ready to start planning (preparation stage)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If so, is the patient:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ready to implement it (action stage)",
"     </li>",
"     <li>",
"      Already making the change (maintenance stage)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cost, inconvenience, and lifestyle barriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the cost, lifestyle, and readiness issues identified above, past experience with the recommended behavior is often critical in making a lifestyle change such as stopping smoking or losing weight. Although patients often characterize past experiences as failures, these experiences may provide useful information regarding why they \"failed\" and give clues about what they need to do to succeed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Health beliefs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perceived risk of illness discussed above is relevant to both medication and lifestyle adherence, but the following health beliefs are primarily relevant to making successful lifestyle changes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perceived benefits of lifestyle change &mdash; Patients may need information regarding the connection between exercise, weight reduction, or other lifestyle change and the desired medical outcome. Misinformation or ignorance is common (eg, patients often are not aware that a modest weight loss or increase in exercise can be medically beneficial, or that even infrequent smoking increases the risk of sudden cardiac death). Poor lifestyle assessment by the patient is also common (eg, patients often overestimate the amount of exercise they get on their job).",
"     </li>",
"     <li>",
"      Perceived barriers to lifestyle change &mdash; Personal barrier beliefs may be challenging (eg, \"Smoking is my only pleasure\"), but often may be addressed indirectly (eg, by helping the patient develop other sources of pleasure). Cultural barrier beliefs about lifestyle changes may also need to be discussed (eg, \"If you're too thin, you're not healthy\"), as will peer group beliefs and pressures.",
"     </li>",
"     <li>",
"      Self-efficacy beliefs &mdash; Based upon past experience, patients often believe they are not capable of making recommended lifestyle changes. This is highly predictive of the initial effort in making change [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/22\">",
"       22",
"      </a>",
"      ]. Low self-efficacy can be changed over time with education and positive experiences of success.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Social support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social support for making lifestyle change is particularly important. Absence of support can add to the patient's sense that having an illness or treating it doesn't matter, and may exacerbate depression. Attitudes of spouse, family and friends can support or undermine motivation for medication treatment or lifestyle change. Their specific behaviors can directly affect the ability to adhere to a treatment plan (eg, quitting smoking when a spouse smokes; changing to a low-fat diet when family traditions involve high-fat foods).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     A STRATEGY FOR INCREASING ADHERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians can incorporate knowledge of the above factors into regular patient visits without adding significantly to the amount of time spent with patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Reduce the likelihood of nonadherence in advance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's difficulties in initiating change need to be addressed at the time recommendations for medications or lifestyle changes are made.",
"   </p>",
"   <p>",
"    The following initial measures may therefore improve patient adherence and outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide a rationale for the treatment in the patient's language &mdash; Caregivers should identify and support the patient's positive, personal reasons for treatment and lifestyle changes, address misperceptions of illness risk and reinforce the positive medical benefits of treatment.",
"     </li>",
"     <li>",
"      Use Motivational Interviewing strategies where possible [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/24,25\">",
"       24,25",
"      </a>",
"      ] &mdash; Perhaps the most difficult task of a clinical encounter that includes a discussion of adherence is conducting it in such as way as to allow the patient to maintain a high level of personal motivation for adherence to treatment after the encounter. &nbsp;Motivational Interviewing strategies such as eliciting the patient's perspective on taking medication and making lifestyle changes, expressing acceptance and support for the patient's difficulties and successes, affirming the patient's freedom to choose the best course of action, and accurately identifying and responding to the patient's stage of change have research-based evidence of success in accomplishing this.",
"     </li>",
"     <li>",
"      Identify and address general barriers to adherence &mdash; Formal assessment of general barriers does not need to be conducted with every patient. However, the caregiver should assess suspected cognitive impairment with a mental status examination and suspected psychopathology with questions relating to mood, coping, sleep and appetite disturbance. Caregivers should always assess motivation for treatment by asking why they want to undergo treatment and encouraging them to have personal as well as medical reasons for treatment, and functional illiteracy by asking patients to repeat and explain treatment instructions.",
"     </li>",
"     <li>",
"      Collaborate on the treatment plan &mdash; The patient's health beliefs and concerns should be incorporated into the treatment plan.",
"     </li>",
"     <li>",
"      Identify and address specific barriers to implementation &mdash; The caregiver should assess the patient's stage of change and develop an appropriate stage intervention (",
"      <a class=\"graphic graphic_table graphicRef65493 \" href=\"UTD.htm?15/53/16219\">",
"       table 2",
"      </a>",
"      ); address cost and functional barriers to treatment and barrier beliefs regarding medications or lifestyle changes; and confirm agreement and patient understanding by asking the patient to describe schedule and specific directions for taking medications, or define the lifestyle treatment goal and the method for achieving it.",
"     </li>",
"     <li>",
"      Encourage the patient to obtain social support for treatment &mdash; In making lifestyle changes, family and friends can help with encouragement and motivation during the action stage, and with stimulus control and reinforcement during the maintenance stage (",
"      <a class=\"graphic graphic_table graphicRef52715 \" href=\"UTD.htm?4/25/4507\">",
"       table 3",
"      </a>",
"      ). Support groups of others making similar changes (eg, Mended Hearts) are helpful in reinforcing positive health motivations and behaviors, and in providing good role models.",
"     </li>",
"     <li>",
"      Frequent follow-up &mdash; Phone calls, letters, or Email from nurses or other clinic staff can improve adherence substantially by answering patient questions, monitoring and addressing patient-initiated cessation of treatment, and reinforcing motivation for continuing engagement in medical treatment or lifestyle change.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Identify and address nonadherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In follow-up visits, patient adherence needs to be assessed, and nonadherence dealt with using the following guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess adherence during each appointment by two simple questions: &ldquo;In the past two weeks, what percent of your cholesterol medicine have you taken?&rdquo; (If less than 100 percent) &hellip;&rdquo;What is the main reason you might miss your medication?&rdquo;",
"     </li>",
"     <li>",
"      Ask about medication side effects or problems associated with nonadherence to lifestyle change.",
"     </li>",
"     <li>",
"      Identify nonadherence and distinguish it from ineffectiveness of treatment &mdash; The caregiver should maintain an open, nonjudgmental attitude to encourage truthful discussion about adherence, and assess patient understanding of treatment protocol by asking the patient to describe treatment plan in detail [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19111/abstract/25\">",
"       25",
"      </a>",
"      ]. Patient adherence should be assessed using multiple information sources (treatment outcome, patient report, spouse report, etc), and additional evidence should be obtained as needed (eg, note if prescriptions are being renewed at appropriate times, and, when feasible, have patients bring pill bottles to every doctor visit to examine use). Finally, the clinician should decide whether the percentage of likely nonadherence accounts for treatment ineffectiveness.",
"     </li>",
"     <li>",
"      Address nonadherence from the patient's perspective &mdash; Both general and specific factors influencing adherence should be identified for discussion. Also, discuss nonadherence in the context of the patient's values, but let the patient come to a decision about what should be done (eg, \"You said you wanted to be around to see your grandchildren grow up, but you're not taking your medication. What do you make of that?\").",
"     </li>",
"     <li>",
"      Get help from other clinic staff in monitoring the patient, following-up, and reinforcing positive aspects of adherence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Deal with continuing nonadherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuing nonadherence can be frustrating for the clinician as well as the patient, and can affect their short- and long-term relationship. Although caregivers should actively support adherence, they should also encourage an ongoing discussion about adherence issues from the nonadherent patient's perspective. While acknowledging patient concerns, caregivers can help patients notice symptom remission and improved laboratory results associated with treatment and lifestyle change and can encourage them to find social support or assistance for adherence.",
"   </p>",
"   <p>",
"    In addition, health care providers should decide how continuing nonadherence will affect their relationship with the patient. If necessary, clinicians should give patient conditions to meet if they expect to continue treatment. However, offering understanding and being willing to work with a nonadherent patient may improve future adherence or adherence with other caregivers. Clinicians should also remain patient since progress may be slow and meaningful change often takes time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       \"Patient information: Reducing the costs of medicines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=see_link\">",
"       \"Patient information: Dealing with side effects from medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H529650870\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adherence to lipid-altering medications and lifestyle changes are associated with better clinical outcomes. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient factors that can affect adhering to treatments include cognitive impairment, psychopathology, the patient&rsquo;s motivation for treatment, and the patient&rsquo;s health literacy. Other general factors affecting adherence include patient-clinician interactions and how follow-up is arranged. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General factors affecting treatment adherence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors specific to medication adherence include medication side effects, the complexity of the medication regimen, the burdens of medication adherence (eg, cost, inconvenience, and required changes in lifestyle), and patient beliefs about medication therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Specific factors affecting adherence to lipid-altering medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors specific to lifestyle adherence include the patient&rsquo;s readiness to make changes, the burdens of lifestyle changes, patient beliefs about lifestyle changes, and the availability of social support for lifestyle changes. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Specific factors affecting adherence to lifestyle recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians can work to increase the likelihood of adherence preemptively by explaining the rationale for treatment in language the patient can understand, using motivational interviewing techniques, identifying and addressing potential barriers to adherence, and collaborating on the plan of treatment. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Reduce the likelihood of nonadherence in advance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinicians should identify nonadherence and its causes by asking nonjudgmental questions about adherence, and by asking about medication side effects and the burdens of lifestyle changes. Clinicians should try to address issues by working from the patient&rsquo;s perspective. An excellent clinician-patient relationship is key. The clinician must work toward establishing a collaborative process for problem solving. &nbsp;(See",
"      <a class=\"local\" href=\"#H21\">",
"       'Identify and address nonadherence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/1\">",
"      Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/2\">",
"      Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/3\">",
"      Shepherd J. The West of Scotland Coronary Prevention Study (WOSCOPS): Benefits of pravastatin therapy in compliant subjects. Circulation 1996; 94(Suppl):I-539.",
"     </a>",
"    </li>",
"    <li>",
"     The Zitter Group's Congress on Health Outcomes and Accountability. Pharmaceutical therapy and care: Its role in outcomes, research and disease management. December 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/5\">",
"      Wilson PW. Established risk factors and coronary artery disease: the Framingham Study. Am J Hypertens 1994; 7:7S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/6\">",
"      Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med 2011; 171:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/7\">",
"      Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 1997; 95:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/8\">",
"      Fernandez F. Depression and its treatment in cardiac patients. Tex Heart Inst J 1993; 20:188.",
"     </a>",
"    </li>",
"    <li>",
"     Stone MH. he borderline syndrome: Constitution, personality, and adaptation, McGraw-Hill, New York 1980.",
"    </li>",
"    <li>",
"     Wise MG, Rundell JR. Concise Guide to Consultation Psychiatry, 2nd ed, American Psychiatric Press, Washington, DC 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/11\">",
"      Dew MA, Roth LH, Thompson ME, et al. Medical compliance and its predictors in the first year after heart transplantation. J Heart Lung Transplant 1996; 15:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/12\">",
"      Williams GC, Grow VM, Freedman ZR, et al. Motivational predictors of weight loss and weight-loss maintenance. J Pers Soc Psychol 1996; 70:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/13\">",
"      Levine J, Warrenburg S, Kerns R, et al. The role of denial in recovery from coronary heart disease. Psychosom Med 1987; 49:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/14\">",
"      Williams MV, Parker RM, Baker DW, et al. Inadequate functional health literacy among patients at two public hospitals. JAMA 1995; 274:1677.",
"     </a>",
"    </li>",
"    <li>",
"     Roter D. Which facets of communication have strong effects on outcome &mdash; A meta-analysis. In: Communicating with Medical Patients, Stewart M, Roter D (Eds), Sage Publications, Newbury Park, CA 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/16\">",
"      Putting a premium on patient satisfaction. Manag Care 1995; 4:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/17\">",
"      Baker D, Roberts DE, Newcombe RG, Fox KA. Evaluation of drug information for cardiology patients. Br J Clin Pharmacol 1991; 31:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/18\">",
"      DeBusk RF, Miller NH, Superko HR, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994; 120:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/19\">",
"      Schmittdiel JA, Karter AJ, Dyer W, et al. The comparative effectiveness of mail order pharmacy use vs. local pharmacy use on LDL-C control in new statin users. J Gen Intern Med 2011; 26:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/20\">",
"      Becker MH, Maiman LA. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 1975; 13:10.",
"     </a>",
"    </li>",
"    <li>",
"     Rosenstock IM. The Health Belief Model: Explaining health behavior through expectancies. In: Health Behavior and Health Education, Glanz K, et al (Eds), Jossey-Bass, San Francisco 1990.",
"    </li>",
"    <li>",
"     Turk D, Meichenbaum D. Adherence to self-care regimens. In: Handbook of Clinical Psychology in Medical Settings, Sweet JJ, Rozensky RH, Tovian SM (Eds), Plenum Press, New York 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/23\">",
"      Prochaska JO, Velicer WF, Rossi JS, et al. Stages of change and decisional balance for 12 problem behaviors. Health Psychol 1994; 13:39.",
"     </a>",
"    </li>",
"    <li>",
"     Miller WM, Rollnick S. Motivational Interviewing : Preparing people for change, 2nd ed, Guilford Press, New York 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19111/abstract/25\">",
"      Butterworth SW. Influencing patient adherence to treatment guidelines. J Manag Care Pharm 2008; 14:21.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4547 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-61.234.146.186-FE4A772EBF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19111=[""].join("\n");
var outline_f18_42_19111=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H529650870\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL FACTORS AFFECTING TREATMENT ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Psychopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Motivation for treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Functional illiteracy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Interactions with clinicians",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Lack of clinical follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SPECIFIC FACTORS AFFECTING ADHERENCE TO LIPID-ALTERING MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Side effects of medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Complexity and organization of regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cost, inconvenience, and lifestyle barriers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Health beliefs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SPECIFIC FACTORS AFFECTING ADHERENCE TO LIFESTYLE RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Stage of change",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cost, inconvenience, and lifestyle barriers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Health beliefs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Social support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      A STRATEGY FOR INCREASING ADHERENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Reduce the likelihood of nonadherence in advance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Identify and address nonadherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Deal with continuing nonadherence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H529650870\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4547\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4547|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/5/21598\" title=\"figure 1\">",
"      Pravastatin prevents CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4547|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/42/7851\" title=\"table 1\">",
"      Health belief model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/53/16219\" title=\"table 2\">",
"      Interventions based on stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/25/4507\" title=\"table 3\">",
"      Strategies increase adherence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=related_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17609?source=related_link\">",
"      Literacy and patient care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_42_19112="Intracranial epidural hematoma in adults";
var content_f18_42_19112=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intracranial epidural hematoma in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/42/19112/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/42/19112/contributors\">",
"     William McBride, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/42/19112/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/42/19112/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/42/19112/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/42/19112/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/42/19112/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subdural hematoma (SDH) and epidural hematoma (EDH) are characterized by bleeding into the spaces surrounding the brain or spinal cord.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subdural hematomas form between the dura and the arachnoid membranes",
"     </li>",
"     <li>",
"      Epidural hematomas arise in the potential space between the dura and the skull",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical issues related to EDH in adults will be reviewed here. EDH in children and subdural hematoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11222?source=see_link\">",
"     \"Intracranial epidural hematoma in children: Epidemiology, anatomy and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=see_link\">",
"     \"Intracranial epidural hematoma in children: Clinical features, evaluation, and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6936?source=see_link\">",
"     \"Subdural hematoma in adults: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;EDH is an uncommon, but serious complication of head injury. While the exact incidence is unknown, it is found in 1 to 4 percent of traumatic head injury cases, and 5 to 15 percent of autopsy series [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of EDH is highest among adolescents and young adults. In observational studies, the mean age of patients with EDH is between 20 and 30 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/2\">",
"     2",
"    </a>",
"    ]. EDH is rare in patients older than 50 to 60 years of age.",
"   </p>",
"   <p>",
"    Most cases of EDH are due to head trauma caused by traffic accidents, falls, and assaults. Skull fractures are present in 75 to 95 percent of patients.",
"   </p>",
"   <p>",
"    In the setting of closed head injury, the linear translation of acceleration along the diameter of the skull in the lateral direction can produce injury to veins, arteries, or brain parenchyma, resulting in SDH, EDH, or coup-countercoup contusions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, thalamic lesions and secondary brainstem injury may develop as a consequence of the mass effect produced by a large EDH or SDH.",
"   </p>",
"   <p>",
"    Key differences between SDH and EDH are readily demonstrable by unenhanced CT of the head. EDH does not cross sutural margins, but does cross dural attachments because it is located in the potential space between dura and skull. As a result, EDH characteristically has a lens-shaped appearance. In comparison, SDH can cross sutural margins, but is limited by dural attachments and therefore appears as a crescent-shaped extra-axial lesion.",
"   </p>",
"   <p>",
"    EDH in adults is most commonly (approximately 85 percent of cases) due to arterial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The major cause of arterial injury is trauma to the skull base with associated tearing of the middle meningeal artery as it courses through the foramen spinosum, resulting in hemorrhage over the cerebral convexity in the middle cranial fossa. In addition, EDH is occasionally found in the anterior cranial fossa, owing to rupture of the anterior meningeal artery, and rarely due to a dural arteriovenous fistula at the vertex [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In approximately 15 percent of cases, injury to one of the dural sinuses, or the confluence of sinuses in the posterior cranial fossa, proves to be the source of hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nontraumatic acute EDH is rare. Potential etiologies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infection, coagulopathy, congenital anomalies, vascular malformations of the dura, and hemorrhagic tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Complication of neurosurgical procedures",
"     </li>",
"     <li>",
"      Epidural abscess, leading to pressure necrosis of meningeal vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pregnancy, sickle cell disease, systemic lupus erythematosus, open heart surgery, Paget disease of the skull, and hemodialysis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/6,8-13\">",
"       6,8-13",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Postulated mechanisms of EDH during hemodialysis include fluctuations of intracranial pressure,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    administration, hypertension in the presence of anticoagulation, and uremic platelet dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/11,14\">",
"     11,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, spinal epidural hematomas may form spontaneously or as complications of spinal procedures or spinal anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with subdural hematoma, the initial presentation of EDH has a spectrum of manifestations. Severe head trauma may result in EDH with coma, while a lesser injury may produce EDH with only momentary loss of consciousness.",
"   </p>",
"   <p>",
"    In some patients with acute EDH and transient loss of consciousness, there is a so-called \"lucid interval\" with recovery of consciousness, followed by deterioration over a period of hours due to continued arterial bleeding and hematoma expansion. This deterioration is typically associated with symptoms such as headache, vomiting, drowsiness, confusion, aphasia, seizures, and hemiparesis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/2,17\">",
"     2,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review, a lucid interval followed by deterioration was observed in 456 of 963 patients (47 percent) who had surgery for EDH [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/2\">",
"     2",
"    </a>",
"    ]. A similar sequence can be seen with EDH due to venous bleeding, with the exception that the neurologic decline is typically slower, occurring over days to weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In any of the above settings, unchecked hematoma expansion leads to elevated intracranial pressure and clinical signs, such as an ipsilateral dilated pupil (due to uncal herniation with compression of the oculomotor nerve), or the Cushing reflex (ie, hypertension, bradycardia, and respiratory",
"    <span class=\"nowrap\">",
"     depression/irregularity).",
"    </span>",
"    Such events will culminate in brain herniation and death unless immediate decompression is undertaken.",
"   </p>",
"   <p>",
"    Approximately 7 to 14 percent of traumatic intracranial EDHs occur in the posterior fossa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/18\">",
"     18",
"    </a>",
"    ]. Such patients may present with elevated intracranial pressure due to venous sinus obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/19\">",
"     19",
"    </a>",
"    ]. In some instances, cortical blindness is observed secondary to bioccipital dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spinal EDH may present with signs that include local back pain, paraparesis, sensory loss with a discernible level, and bowel or bladder incontinence. Urgent MRI of the spine is warranted if there is clinical suspicion of spinal EDH. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Spine MRI'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of acute head trauma, imaging serves a key role in both diagnosis and appropriate initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition to EDH, head trauma is a major cause of a variety of other central nervous system lesions including subdural hematoma, subarachnoid hemorrhage, cerebral contusion, diffuse brain swelling, and laceration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. Any of these injuries may coexist in a given patient following trauma, and their clinical manifestations can be difficult to distinguish. However, it is important to identify the specific nature of the lesion during initial evaluation, since potentially life-saving treatment will differ with the lesion.",
"   </p>",
"   <p>",
"    Lumbar puncture is contraindicated in cases where a space-occupying lesion such as EDH is suspected, due to the risk of herniation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Head CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) of the head is the most widely used imaging study for acute head trauma owing to its speed, relative simplicity, and widespread availability [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/21\">",
"     21",
"    </a>",
"    ]. Epidural blood produces a lens-shaped pattern on head CT because its collection is limited by firm dural attachments at the cranial sutures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60726 \" href=\"UTD.htm?3/40/3716\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, heterogeneous foci of lower attenuation appear within an acute EDH. This finding of a mixed density blood clot (or swirl sign) indicates active extravasation of blood and represents an indication for immediate surgical evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, acute EDH may not be apparent on initial head CT in up to 8 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/22\">",
"     22",
"    </a>",
"    ]. Several issues may be associated with a nondiagnostic head CT, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe anemia, which lowers the density of the hemorrhage",
"     </li>",
"     <li>",
"      Severe hypotension, which reduces the rate of arterial extravasation",
"     </li>",
"     <li>",
"      Early scanning after trauma, before enough blood has accumulated to be visible on imaging",
"     </li>",
"     <li>",
"      Venous bleeding with slow accumulation of blood",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Hematoma volume estimation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematoma volume influences management decisions in adult patients with acute EDH because it correlates with outcome. The hematoma volume can be estimated quickly from the head CT scan by using the formula",
"    <span class=\"nowrap\">",
"     ABC/2,",
"    </span>",
"    which approximates the volume of an ellipsoid. This formula was originally used to estimate intracerebral hemorrhage volume, but can be applied to EDH as well [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The formula is calculated using the centimeter scale on the CT images as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A is the greatest hemorrhage diameter on the CT slice with the largest area of hemorrhage",
"     </li>",
"     <li>",
"      B is the largest diameter 90 degrees to A on the same CT slice",
"     </li>",
"     <li>",
"      C is the approximate number of CT slices with hemorrhage multiplied by the slice thickness in centimeters",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To calculate C, each CT slice with hemorrhage is visually compared to the CT slice with the largest hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/23\">",
"     23",
"    </a>",
"    ]. An individual hemorrhage slice is counted as one full slice for determining C if the hemorrhage area is &gt;75 percent of the area on the slice with the largest hemorrhage. A slice is counted as one-half if the hemorrhage area is approximately 25 to 75 percent of the area on the largest hemorrhage slice. The slice is not counted if the area is &lt;25 percent of the largest hemorrhage slice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Brain MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although head CT is more widely used, brain magnetic resonance imaging (MRI) is more sensitive than head CT for the detection of intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/24\">",
"     24",
"    </a>",
"    ]. MRI is especially useful in the diagnosis EDH at the vertex [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/25\">",
"     25",
"    </a>",
"    ]. In most centers, MRI is an adjunct to CT in the evaluation of acute head trauma and is used for situations in which there is a strong suspicion for EDH or subdural hematoma, but no clear evidence of hematoma by CT.",
"   </p>",
"   <p>",
"    The MRI signal appearance of EDH and subdural hematoma evolves over time in a manner similar to that observed in parenchymal hematoma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77358 \" href=\"UTD.htm?30/26/31139\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The acute clot is hypointense on T2-weighted images due to the presence of deoxyhemoglobin.",
"     </li>",
"     <li>",
"      Over subsequent weeks, deoxyhemoglobin degrades to methemoglobin, which appears bright on both T1 and T2-weighted images.",
"     </li>",
"     <li>",
"      At several months, only hemosiderin remains, and the clot again becomes hypointense on the T1-weighted images.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Spine MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is preferred if spinal pathology such as EDH is suspected, since it provides superior resolution compared to CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under some conditions, cerebral angiography is indicated for the evaluation of EDH. As an example, EDH located at the vertex can originate from a dural arteriovenous fistula of the middle meningeal artery. In this setting, angiography is necessary to fully evaluate the possibility of an underlying vascular lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/4,26\">",
"     4,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data regarding outcome after EDH are mainly from observational studies. In surgical series, mortality after EDH in adults and children is approximately 10 and 5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/2\">",
"     2",
"    </a>",
"    ]. The full range of outcomes is illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study that prospectively collected data for 107 consecutive patients with EDH, the overall mortality was 5 percent, and there were no deaths among patients with a Glasgow coma scale score &ge;8 who underwent hematoma evacuation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/27\">",
"       27",
"      </a>",
"      ]. At six months after injury, a good recovery was observed in 89 percent of the cohort.",
"     </li>",
"     <li>",
"      In a retrospective review of 139 adult patients with EDH admitted to an intensive care unit, 46 percent had a good recovery, 31 percent were moderately disabled, 10 percent were severely disabled, 4 percent were vegetative, and 9 percent expired [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prognostic indicators",
"    </span>",
"    &nbsp;&mdash;&nbsp;In observational studies, the following variables have been associated with unfavorable outcome from EDH [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low Glasgow coma scale (GCS) score on admission or before surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/27,29-31\">",
"       27,29-31",
"      </a>",
"      ]. The GCS grades coma severity according to three categories of responsiveness: best eye opening, best verbal, and best motor response. The GCS is scored between 3 and 15, with higher scores indicating better performance (",
"      <a class=\"graphic graphic_table graphicRef81854 \" href=\"UTD.htm?28/62/29676\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Presence of pupillary abnormalities, particularly contralateral or bilateral unreactive pupils [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/30-34\">",
"       30-34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Older age [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Longer time interval between neurologic deterioration and surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/32,35\">",
"       32,35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Postoperative elevated intracranial pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/28,34\">",
"       28,34",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, several studies have identified head CT findings that correlate with poor outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hematoma volume &gt;30 to 150 cm^3 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/30,33\">",
"       30,33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Presence of midline shift &gt;10 to 12 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mixed density blood clot, indicating acute bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Presence of associated intracranial lesions such as contusions, intracerebral hemorrhage, subarachnoid hemorrhage, and diffuse brain swelling [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/30,31,33,35\">",
"       30,31,33,35",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute symptomatic EDH is a neurologic emergency that often requires surgical treatment to prevent irreversible brain injury and death caused by hematoma expansion, elevated intracranial pressure, and brain herniation. Select patients who present in good clinical condition with small volume EDH can be managed nonoperatively as long as they remain stable. Close observation and serial brain imaging is an important aspect of nonoperative management, since hematoma enlargement and neurologic deterioration requiring surgery may occur in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Craniotomy and hematoma evacuation is the mainstay of surgical treatment of symptomatic acute EDH. When indicated, identification and ligation of the bleeding vessel must be undertaken. However, there are few data comparing different surgical techniques. Burr hole evacuation (trephination) has been used for acute EDH, and may be lifesaving if access to neurosurgical expertise is limited or likely to be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/36\">",
"     36",
"    </a>",
"    ]. Open craniotomy affords a more complete evacuation of the hematoma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The decision to perform surgery in patients with acute EDH is based primarily upon the patient's neurologic status, as assessed by the Glasgow coma score (GCS) score, neurologic examination and pupillary signs, and brain imaging findings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available evidence, though limited, suggests that surgery should be performed within one to two hours after head trauma, or the onset of neurologic deterioration, for comatose patients with acute EDH and signs of brain herniation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series of patients with acute EDH compared surgery within two hours after onset of coma (n = 18) with later surgery (n = 16). Patients who had early evacuation had a significantly lower mortality rate (17 versus 56 percent) and higher rate of good recovery (67 versus 13 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another series of adults with acute EDH and admission GCS score &lt;8 included 10 patients who developed new anisocoria after admission [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/32\">",
"       32",
"      </a>",
"      ]. Five patients had craniotomy more than 90 minutes after onset of anisocoria, and all of these patients died. Another five patients had craniotomy within 70 minutes after anisocoria onset, and all survived with either good recovery or moderate disability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nonoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have compared surgery with conservative management for patients with EDH, but retrospective data suggest that stable patients with EDH who have small hematomas and mild symptoms can be managed nonoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Hematoma enlargement and neurologic deterioration requiring surgery may occur in such patients, particularly in the first 8 to 36 hours after injury, and patients with temporal EDH may be at higher risk. Thus, close observation and serial brain imaging is an important aspect of nonoperative management. Supporting evidence is found in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series reported 74 patients with traumatic EDH and good initial clinical status (GCS score &gt;12) who were managed nonoperatively [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/40\">",
"       40",
"      </a>",
"      ]. Neurologic deterioration occurred in 14 patients (19 percent) prompting delayed surgery. Patients requiring surgery were more likely to have EDH volume &gt;30 mL, clot thickness &gt;15 mm, and midline shift &gt;5 mm, than those who did not have surgery. All patients in this series achieved a good outcome.",
"     </li>",
"     <li>",
"      In another series, 80 patients (5 to 68 years old) with EDH were admitted within 24 hours of traumatic brain injury and selected for nonoperative management on the basis of a GCS score &gt;8, an EDH volume &lt;30 mL (&lt;30 cm^3), and clot thickness &lt;20 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/39\">",
"       39",
"      </a>",
"      ]. Five patients experienced subsequent neurologic deterioration and hematoma enlargement prompting surgical evacuation. One of these patients died and four had a good outcome. Temporal lobe EDH was present in all five patients (100 percent) with deterioration, and in 18 of 75 patients (24 percent) without deterioration; the difference between these groups was statistically significant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The head CT should be repeated serially for patients with acute EDH who are managed without surgery, as there is a high incidence of early hematoma enlargement.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 160 adult patients with EDH who were managed nonoperatively, hematoma expansion on follow-up head CT was observed in 23 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/41\">",
"       41",
"      </a>",
"      ]. The mean time to enlargement after injury was eight hours, and enlargement occurred within 36 hours after injury in all cases where it was observed.",
"     </li>",
"     <li>",
"      Another retrospective study evaluated patients who had two head CT scans in the first 24 hours after traumatic brain injury, with a mean time to follow-up scan of seven hours [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/42\">",
"       42",
"      </a>",
"      ]. Early hemorrhage expansion was seen in 22 percent of patients with EDH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Progressive hematoma enlargement of small EDHs over several weeks has also been reported in patients followed by serial CT [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Calcification and ossification of persistent EDH has been reported and would suggest a need for surgical evacuation of EDHs that do not spontaneously absorb over the course of serial follow-up examinations, even if the patient's clinical condition is good [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Deciding who needs surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with focal neurologic signs or symptoms attributable to acute EDH require emergent surgical hematoma evacuation to prevent irreversible brain injury or death caused by hematoma expansion, elevated intracranial pressure, and brain herniation. In initially awake patients with mildly symptomatic EDH, hematoma growth causing elevated intracranial pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progressive decline in neurologic status also warrants surgery.",
"   </p>",
"   <p>",
"    Guidelines from an expert panel published in 2006 recommend surgical evacuation for all adult patients with acute EDH and hematoma volume &gt;30 cm^3 (&gt;30 mL) regardless of the Glasgow coma score (GCS) score [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/2\">",
"     2",
"    </a>",
"    ]. Urgent surgical evacuation is recommended for patients with acute EDH and coma (GCS score &lt;9) who have pupillary abnormalities (anisocoria).",
"   </p>",
"   <p>",
"    Nonoperative management is considered an option for mildly symptomatic patients with acute EDH who meet all of the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      EDH volume &lt;30 cm^3 with clot thickness &lt;15 mm on head CT and midline shift of &lt;5 mm",
"     </li>",
"     <li>",
"      No coma (GCS score &gt;8) and no focal neurologic deficits",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines recommend serial head CT scanning and close neurologic observation in an experienced neurosurgical center for nonoperatively managed patients with acute EDH. The first follow-up CT scan should be obtained six to eight hours after head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to the guidelines, we recommend urgent surgical hematoma evacuation for patients with acute EDH who are comatose on admission or have early signs of herniation, such as unilateral or bilateral pupillary dilation, given the potential for recovery.",
"   </p>",
"   <p>",
"    For patients with acute EDH who are awake and have no focal neurologic deficits, we suggest management based upon the size of the hematoma and the degree of midline shift. Patients with a small hematoma (hematoma volume &lt;30 cm^3 and clot thickness &lt;15 mm and midline shift &lt;5 mm on brain imaging) are managed nonoperatively with close observation. Those not meeting these criteria are managed surgically.",
"   </p>",
"   <p>",
"    We recommend urgent surgical hematoma evacuation (within 90 minutes) for patients who have initially good clinical status but deteriorate with signs of brain herniation or elevated intracranial pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Reversing anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coexistent anticoagulation in patients with either traumatic or spontaneous EDH is not uncommon and must be reversed before surgical intervention. Ideally, anticoagulation should also be reversed for those patients who are managed nonoperatively. However, the potential benefit of reversing anticoagulation (a reduced risk of hematoma enlargement) must be weighed against the risk related to the underlying need for anticoagulation in this group (eg, atrial fibrillation, mechanical heart valve, etc.).",
"   </p>",
"   <p>",
"    For patients on oral anticoagulant therapy who require emergent neurosurgery,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    reversal with unactivated prothrombin complex concentrates (PCC, also called factor IX complex) provides a rapid correction of the international normalized ratio (INR) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"     Recombinant human factor VIIa",
"    </a>",
"    (rFVIIa) and unactivated PCC have been studied for the treatment of anticoagulant-associated intracerebral hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19112/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=see_link&amp;anchor=H22#H22\">",
"     \"Spontaneous intracerebral hemorrhage: Prognosis and treatment\", section on 'Hemostatic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, rFVIIa and FIXCC are investigational and unproven in the management of EDH. They should be not be used routinely outside the context of a clinical trial or institutional treatment protocol at expert centers.",
"   </p>",
"   <p>",
"    Our approach to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    reversal is similar to that recommended for patients with intracerebral hemorrhage associated with oral anticoagulant therapy: (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=see_link\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate cessation of all anticoagulant and antiplatelet therapy",
"     </li>",
"     <li>",
"      Vitamin K 10 mg by slow intravenous infusion",
"     </li>",
"     <li>",
"      Infusion of unactivated PCC, or fresh frozen plasma (FFP) if unactivated PCC is not available. As noted above, therapy with rFVIIa or FIXCC should be used only in the context of a clinical trial or a treatment protocol at experienced centers (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=see_link&amp;anchor=H26#H26\">",
"       \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Choice of agent'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goal of therapy should be an INR in the normal range (ie, &lt;1.2 in most laboratories).",
"   </p>",
"   <p>",
"    Calculation of the dose of unactivated PCC (in International Units) or FFP (in mL) can be estimated based upon the patient's initial INR and body weight. This is outlined in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H15#H15\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Significant or life-threatening bleeding'",
"    </a>",
"    .) The dose of PCC is based on the factor IX content of the preparation; after initial infusion of 500 to 1000 international units at a rate of 100 international",
"    <span class=\"nowrap\">",
"     units/min,",
"    </span>",
"    subsequent infusion of PCC should be at a rate of &le;25 international",
"    <span class=\"nowrap\">",
"     units/min.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with EDH may develop elevated intracranial pressure requiring urgent intervention. Definitive therapy is usually hematoma evacuation; medical resuscitation techniques include head elevation, hyperventilation, and osmotic diuresis with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    . The management of elevated intracranial pressure is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Glucocorticoid therapy is NOT indicated following head injury, and may be associated with increased acute mortality. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=see_link&amp;anchor=H33#H33\">",
"     \"Evaluation and management of elevated intracranial pressure in adults\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidural hematoma (EDH) is caused by bleeding in the potential space between the dura and the skull, usually as a consequence of traumatic injury. Nontraumatic acute EDH is rare. The incidence of EDH is highest among adolescents and young adults. EDH is rare in patients older than 50 to 60 years of age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The source of blood in EDH is most often arterial, but 15 percent of cases are due to venous bleeding. The major cause of arterial injury is trauma to the sphenoid bone with associated tearing of the middle meningeal artery, resulting in hemorrhage over the cerebral convexity in the middle cranial fossa. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical manifestations of EDH are highly variable, and include altered consciousness, headache, vomiting, drowsiness, confusion, aphasia, seizures, and hemiparesis. Some patients with acute EDH and transient loss of consciousness have a \"lucid interval\" with recovery of consciousness, followed by deterioration due to hematoma enlargement. Spinal EDH may present with signs that include local back pain, paraparesis, sensory loss with a discernible level, and bowel or bladder incontinence. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Head CT is a fast and accurate method for the detection of acute intracranial hemorrhage. Epidural blood produces a lens-shaped pattern on head CT. Brain MRI has a higher sensitivity than CT and can be useful when diagnostic uncertainty exists. In addition to EDH, head trauma may cause subdural hematoma, subarachnoid hemorrhage, cerebral contusion, diffuse brain swelling, and laceration. These injuries frequently coexist following trauma. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients have a good recovery after EDH, but mortality in adults and children is approximately 10 and 5 percent, respectively. Factors associated with prognosis include the severity of neurologic deficits (generally quantified by the Glasgow coma scale [GCS] score), presence of pupillary abnormalities, hematoma volume, the degree of midline brain shift, and the presence and severity of associated trauma. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with focal neurologic signs or symptoms attributable to acute EDH require emergent surgical hematoma evacuation to prevent irreversible brain injury or death caused by hematoma expansion, elevated intracranial pressure, and brain herniation. Even in patients who are comatose on admission or have early signs of brain herniation, we recommend urgent surgical hematoma evacuation given the potential for recovery (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adult patients with acute EDH who are awake and have no focal neurologic deficits, we suggest management based upon the size of the hematoma and the degree of midline shift (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients who have a small (&lt;30 cm^3) hematoma with clot thickness &lt;15 mm and midline shift &lt;5 mm on brain imaging are managed nonoperatively with close observation, while those not meeting these criteria are managed surgically. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Hematoma volume estimation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonoperative management of acute EDH requires close observation and serial brain imaging because of the risk of hematoma enlargement and neurologic deterioration. Thus, we recommend obtaining the first follow-up head CT scan no later than six to eight hours after head injury. For patients with acute EDH who have initially good clinical status but deteriorate with signs of brain herniation or elevated intracranial pressure, we recommend urgent surgical hematoma evacuation within 90 minutes of the onset of deterioration (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30802978\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to thank Dr. David Brock, who contributed to an earlier version of this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Mayer S, Rowland L. Head injury. In: Merritt's Neurology, Rowland L.  (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2000. p.401.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/2\">",
"      Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of acute epidural hematomas. Neurosurgery 2006; 58:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/3\">",
"      Besenski N. Traumatic injuries: imaging of head injuries. Eur Radiol 2002; 12:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/4\">",
"      Matsumoto K, Akagi K, Abekura M, Tasaki O. Vertex epidural hematoma associated with traumatic arteriovenous fistula of the middle meningeal artery: a case report. Surg Neurol 2001; 55:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/5\">",
"      McIver JI, Scheithauer BW, Rydberg CH, Atkinson JL. Metastatic hepatocellular carcinoma presenting as epidural hematoma: case report. Neurosurgery 2001; 49:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/6\">",
"      Ng WH, Yeo TT, Seow WT. Non-traumatic spontaneous acute epidural haematoma -- report of two cases and review of the literature. J Clin Neurosci 2004; 11:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/7\">",
"      Moonis G, Granados A, Simon SL. Epidural hematoma as a complication of sphenoid sinusitis and epidural abscess: a case report and literature review. Clin Imaging 2002; 26:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/8\">",
"      Szkup P, Stoneham G. Case report: spontaneous spinal epidural haematoma during pregnancy: case report and review of the literature. Br J Radiol 2004; 77:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/9\">",
"      Jea A, Moza K, Levi AD, Vanni S. Spontaneous spinal epidural hematoma during pregnancy: case report and literature review. Neurosurgery 2005; 56:E1156; discussion E1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/10\">",
"      Takahashi K, Koiwa F, Tayama H, et al. A case of acute spontaneous epidural haematoma in a chronic renal failure patient undergoing haemodialysis: successful outcome with surgical management. Nephrol Dial Transplant 1999; 14:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/11\">",
"      Shimokawa S, Hayashi T, Anegawa S, et al. [Spontaneous epidural hematoma in a patient undergoing hemodialysis: a case report]. No To Shinkei 2003; 55:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/12\">",
"      Naran AD, Fontana L. Sickle cell disease with orbital infarction and epidural hematoma. Pediatr Radiol 2001; 31:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/13\">",
"      Mart&iacute;nez-Lage JF, Saez V, Requena L, et al. Cranial epidural hematoma in Paget's disease of the bone. Intensive Care Med 2000; 26:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/14\">",
"      Shahlaie K, Fox A, Butani L, Boggan JE. Spontaneous epidural hemorrhage in chronic renal failure. A case report and review. Pediatr Nephrol 2004; 19:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/15\">",
"      Awad JN, Kebaish KM, Donigan J, et al. Analysis of the risk factors for the development of post-operative spinal epidural haematoma. J Bone Joint Surg Br 2005; 87:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/16\">",
"      Sokolowski MJ, Garvey TA, Perl J 2nd, et al. Prospective study of postoperative lumbar epidural hematoma: incidence and risk factors. Spine (Phila Pa 1976) 2008; 33:108.",
"     </a>",
"    </li>",
"    <li>",
"     Victor M, Ropper A. Craniocerebral trauma. In: Adams and Victor's Principles of Neurology, 7th ed, Victor M, Ropper A.  (Eds), McGraw-Hill, New York 2001. p.925.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/18\">",
"      Radulovi D, Tasi G, Jokovic M. [Epidural hematomas of the posterior fossa]. Vojnosanit Pregl 2004; 61:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/19\">",
"      Owler BK, Besser M. Extradural hematoma causing venous sinus obstruction and pseudotumor cerebri syndrome. Childs Nerv Syst 2005; 21:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/20\">",
"      Yilmazlar S, Taskapilioglu O, Aksoy K. Transient Anton's syndrome: a presenting feature of acute epidural hematoma at the confluens sinuum. Pediatr Neurosurg 2003; 38:156.",
"     </a>",
"    </li>",
"    <li>",
"     Grossman RI. Head Trauma. In: Neuroradiology: The Requisites, 2nd ed, Mosby, Philadelphia 2003. p.243.",
"    </li>",
"    <li>",
"     Epidural hematoma. In: Color atlas of emergency trauma. Mandavia, DP, Newton, EJ, Demetriades (Eds), Cambridge University Press, New York 2003. p.11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/23\">",
"      Kothari RU, Brott T, Broderick JP, et al. The ABCs of measuring intracerebral hemorrhage volumes. Stroke 1996; 27:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/24\">",
"      Gentry LR, Godersky JC, Thompson B, Dunn VD. Prospective comparative study of intermediate-field MR and CT in the evaluation of closed head trauma. AJR Am J Roentgenol 1988; 150:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/25\">",
"      Miller DJ, Steinmetz M, McCutcheon IE. Vertex epidural hematoma: surgical versus conservative management: two case reports and review of the literature. Neurosurgery 1999; 45:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/26\">",
"      Hori E, Ogiichi T, Hayashi N, et al. Case report: acute subdural hematoma due to angiographically unvisualized ruptured aneurysm. Surg Neurol 2005; 64:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/27\">",
"      Bricolo AP, Pasut LM. Extradural hematoma: toward zero mortality. A prospective study. Neurosurgery 1984; 14:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/28\">",
"      Heinzelmann M, Platz A, Imhof HG. Outcome after acute extradural haematoma, influence of additional injuries and neurological complications in the ICU. Injury 1996; 27:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/29\">",
"      Gennarelli TA, Spielman GM, Langfitt TW, et al. Influence of the type of intracranial lesion on outcome from severe head injury. J Neurosurg 1982; 56:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/30\">",
"      Lee EJ, Hung YC, Wang LC, et al. Factors influencing the functional outcome of patients with acute epidural hematomas: analysis of 200 patients undergoing surgery. J Trauma 1998; 45:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/31\">",
"      van den Brink WA, Zwienenberg M, Zandee SM, et al. The prognostic importance of the volume of traumatic epidural and subdural haematomas revisited. Acta Neurochir (Wien) 1999; 141:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/32\">",
"      Cohen JE, Montero A, Israel ZH. Prognosis and clinical relevance of anisocoria-craniotomy latency for epidural hematoma in comatose patients. J Trauma 1996; 41:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/33\">",
"      Rivas JJ, Lobato RD, Sarabia R, et al. Extradural hematoma: analysis of factors influencing the courses of 161 patients. Neurosurgery 1988; 23:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/34\">",
"      Lobato RD, Rivas JJ, Cordobes F, et al. Acute epidural hematoma: an analysis of factors influencing the outcome of patients undergoing surgery in coma. J Neurosurg 1988; 68:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/35\">",
"      Haselsberger K, Pucher R, Auer LM. Prognosis after acute subdural or epidural haemorrhage. Acta Neurochir (Wien) 1988; 90:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/36\">",
"      Nelson JA. Local skull trephination before transfer is associated with favorable outcomes in cerebral herniation from epidural hematoma. Acad Emerg Med 2011; 18:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/37\">",
"      Bullock R, Smith RM, van Dellen JR. Nonoperative management of extradural hematoma. Neurosurgery 1985; 16:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/38\">",
"      Cucciniello B, Martellotta N, Nigro D, Citro E. Conservative management of extradural haematomas. Acta Neurochir (Wien) 1993; 120:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/39\">",
"      Bezirciolu H, Erahin Y, Demir&ccedil;ivi F, et al. Nonoperative treatment of acute extradural hematomas: analysis of 80 cases. J Trauma 1996; 41:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/40\">",
"      Chen TY, Wong CW, Chang CN, et al. The expectant treatment of \"asymptomatic\" supratentorial epidural hematomas. Neurosurgery 1993; 32:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/41\">",
"      Sullivan TP, Jarvik JG, Cohen WA. Follow-up of conservatively managed epidural hematomas: implications for timing of repeat CT. AJNR Am J Neuroradiol 1999; 20:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/42\">",
"      Oertel M, Kelly DF, McArthur D, et al. Progressive hemorrhage after head trauma: predictors and consequences of the evolving injury. J Neurosurg 2002; 96:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/43\">",
"      Chang JH, Choi JY, Chang JW, et al. Chronic epidural hematoma with rapid ossification. Childs Nerv Syst 2002; 18:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/44\">",
"      Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000; 14:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/45\">",
"      Vigu&eacute; B, Ract C, Tremey B, et al. Ultra-rapid management of oral anticoagulant therapy-related surgical intracranial hemorrhage. Intensive Care Med 2007; 33:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19112/abstract/46\">",
"      Siddiq F, Jalil A, McDaniel C, et al. Effectiveness of Factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage. Neurocrit Care 2008; 8:36.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1107 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-09444732DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19112=[""].join("\n");
var outline_f18_42_19112=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Head CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Hematoma volume estimation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Brain MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Spine MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prognostic indicators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nonoperative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Deciding who needs surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Reversing anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30802978\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1107\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1107|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/40/3716\" title=\"diagnostic image 1\">",
"      CT acute traumatic epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/26/31139\" title=\"diagnostic image 2\">",
"      MRI left traumatic EDH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1107|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/62/29676\" title=\"table 1\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33402?source=related_link\">",
"      Evaluation and management of elevated intracranial pressure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/35/10808?source=related_link\">",
"      Intracranial epidural hematoma in children: Clinical features, evaluation, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11222?source=related_link\">",
"      Intracranial epidural hematoma in children: Epidemiology, anatomy and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/56/32650?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6936?source=related_link\">",
"      Subdural hematoma in adults: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_42_19113="Epidemiology and etiology of peptic ulcer disease";
var content_f18_42_19113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and etiology of peptic ulcer disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/42/19113/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/42/19113/contributors\">",
"     Andrew H Soll, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/42/19113/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/42/19113/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/42/19113/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/42/19113/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/42/19113/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptic ulcers are defects in the gastrointestinal mucosa that extend through the muscularis mucosae (",
"    <a class=\"graphic graphic_picture graphicRef63114 \" href=\"UTD.htm?11/37/11871\">",
"     picture 1",
"    </a>",
"    ). They persist as a function of the acid or peptic activity in gastric juice. Peptic ulcer disease (PUD) is an important cause of morbidity and health care costs; estimates of expenditures related to work loss, hospitalization, and outpatient care (excluding medication costs) are $5.65 billion per year in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of peptic ulcer ranges from resolution without intervention to the development of complications with the potential for significant morbidity and mortality, such as bleeding and perforation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40282?source=see_link\">",
"     \"Overview of the complications of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time trends in the epidemiology of peptic ulcer disease reflect complex, multifactorial etiologies. Peptic ulcers were rare before the 1800s. The pathology of gastric ulcers (GUs) was first described in 1835 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/2\">",
"     2",
"    </a>",
"    ]; during the late 1800s the prominent form was GUs in young women. Duodenal ulcers (DUs) were rare until about 1900 and then became a prevalent condition during the first half of the 20",
"    <sup>",
"     th",
"    </sup>",
"    century. However, in developed countries the mortality from peptic ulcer disease has fallen dramatically for birth cohorts born after the turn of the 20",
"    <sup>",
"     th",
"    </sup>",
"    century [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, it is now evident that the epidemiology of peptic ulcer disease largely reflects environmental factors, primarily",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    infection, NSAID use, and smoking. However, these environmental factors do not tell the whole story of the time trends and the birth-cohort effect for peptic ulcer disease. In particular,",
"    <em>",
"     H. pylori",
"    </em>",
"    was a prevalent human infection well before the late 1800s, so that this infection per se cannot explain the rise in ulcer prevalence and shift from GUs to DUs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The influence of environmental factors on the pattern of gastritis may be a key variable in these birth-cohort effects. At the end of the 19",
"    <sup>",
"     th",
"    </sup>",
"    century (and currently in many developing countries)",
"    <em>",
"     H. pylori",
"    </em>",
"    infection was characterized by pangastritis involving the gastric antrum and body and leading to acid hyposecretion, which predisposed to gastric cancer and GUs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. In contrast, DUs are associated with antral-predominant gastritis that spares the acid-secreting body, but is negatively associated with more or severe body gastritis and with gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/8\">",
"     8",
"    </a>",
"    ]. The reason is that DUs require a permissive level of acid secretion which cannot be achieved in the face of moderate body gastritis, whereas gastric cancer is associated with hypochlorhydria.",
"   </p>",
"   <p>",
"    Although still controversial, this dramatic shift in pattern of ulcer disease and of",
"    <em>",
"     H. pylori",
"    </em>",
"    -induced gastritis appeared to reflect environmental factors, which changed markedly during this period, rather than genetic bacterial or host factors, which appeared unchanged. One theory suggests that during the early 1900s improved transportation and refrigeration decreased the need for food preservatives and supported a rapid change in diet across the emerging developed nations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/4\">",
"     4",
"    </a>",
"    ]. The most evident change was from a seasonal diet, in which salt was used as a preservative, to a diet with fresh fruits and vegetables available all year. Furthermore, improved hygiene and overall health in developed countered was associated with reduced rates of childhood infections, which may decrease susceptibility to the pangastritic spread of",
"    <em>",
"     H. pylori",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In developing nations, the majority of children are infected with",
"    <em>",
"     H. pylori",
"    </em>",
"    before the age of 10 and adult prevalence peaks at more than 80 percent before age 50. In contrast, in developed countries such as the United States, serologic evidence of",
"    <em>",
"     H. pylori",
"    </em>",
"    is uncommon before age 10, increasing to 10 percent in those between 18 and 30 years of age, and to 50 percent in those older than age 60 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43271?source=see_link\">",
"     \"Bacteriology and epidemiology of Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the annual incidence of peptic ulcer disease range from 0.1 to 0.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. A systematic review of the worldwide literature estimated that the annual incidence ranged from 0.1 to 0.19 percent for physician-diagnosed PUD and 0.01 to 0.17 percent when based upon hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/13\">",
"     13",
"    </a>",
"    ]. Ulcer incidence increases with age for both DUs and GUs, but DUs emerge two decades earlier than GUs, particularly in males [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/11,14\">",
"     11,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disease burden varies based upon the presence of",
"    <em>",
"     H. pylori",
"    </em>",
"    . The ulcer incidence in",
"    <em>",
"     H. pylori",
"    </em>",
"    -infected individuals is about 1 percent per year, a rate that is 6- to 10-fold higher than for uninfected subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H116189959\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study in the United States reported an endoscopic point prevalence for peptic ulcers in asymptomatic,",
"    <em>",
"     H. pylori",
"    </em>",
"    -positive adults of 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/17\">",
"     17",
"    </a>",
"    ]. Other studies, in presumably asymptomatic subjects in whom",
"    <em>",
"     H. pylori",
"    </em>",
"    status was unknown, have reported an endoscopic point prevalence ranging from 1 and 6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. This rate is 4 to 10 times that found in",
"    <em>",
"     H. pylori",
"    </em>",
"    -negative subjects, but careful comparative studies have not been reported. Several factors contribute to this variability, such as the endoscopic criteria of an ulcer diagnosis, the assessment and criteria for symptoms, the population, and sampling methods.",
"   </p>",
"   <p>",
"    The lifetime prevalence is also higher in",
"    <em>",
"     H. pylori",
"    </em>",
"    -positive subjects (approximately 10 to 20 percent compared to 5 to 10 percent in the general population) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/11,15\">",
"     11,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Trends in prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several prominent trends are evident. Peptic ulcer disease and gastric cancer have been steadily falling over the past several decades [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/3,22\">",
"     3,22",
"    </a>",
"    ]. Rates of DUs have fallen more dramatically than for GUs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/22\">",
"     22",
"    </a>",
"    ]. These trends contrast with the increase in esophagitis and esophageal and cardiac adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the decreases in long-term trends for rates of hospitalization and death from peptic ulcer disease, ulcer complications appear relatively stable over the past two decades [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. However, the picture is complex because these overall trends represent different patterns in subpopulations. As an example, peptic ulcer hemorrhage and perforation have been rapidly declining in younger individuals, especially men, for the past two to three decades, but have been stable or increasing in older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. However, a more recent analysis using a large database from the United States found an approximate 30 to 40 percent fall in hospitalizations for PUD complications between 1993 and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/29\">",
"     29",
"    </a>",
"    ]. A study from a large regional hospital in Sweden confirmed these trends [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although recent updates are not available, the prevalence of peptic ulcer in Western countries appears to have shifted over the second half of the 20",
"    <sup>",
"     th",
"    </sup>",
"    century from being a disease predominant in males to one with a nearly comparable prevalence in both sexes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/11\">",
"     11",
"    </a>",
"    ]. This pattern may not apply to Asian countries, where DUs may still be predominant in males [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These trends are due to the interplay of several factors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of",
"      <em>",
"       H. pylori",
"      </em>",
"      in patients younger than 60 years is falling dramatically in developed countries due in part to improved hygiene and socioeconomic conditions starting after World War II. &nbsp;However, the prevalence of",
"      <em>",
"       H. pylori",
"      </em>",
"      infection remains high for older individuals and in certain predisposed subpopulations. The decline in",
"      <em>",
"       H. pylori",
"      </em>",
"      prevalence is one clear factor accounting for the fall in peptic ulcer prevalence in the developed countries. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43271?source=see_link\">",
"       \"Bacteriology and epidemiology of Helicobacter pylori infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      NSAID use increases as a function of age and is an independent risk factor for ulcers. In addition, older subjects are more likely to develop complications from NSAID ulcers and to suffer increased morbidity and mortality from these complications because of comorbidities. Increased NSAID use, especially in the elderly, opposed the fall in",
"      <em>",
"       H. pylori",
"      </em>",
"      prevalence, and probably accounted for sustained rates in peptic ulcer complications during the past three decades. One can speculate that more judicious use of NSAIDs and possibly measures to ameliorate risk, such as PPI co-therapy or use of COX-2 inhibitors, are finally attenuating ulcer complication rates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"       \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Smoking clearly exacerbates at least",
"      <em>",
"       H. pylori",
"      </em>",
"      associated ulcer disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"       \"Overview of the natural history and treatment of peptic ulcer disease\"",
"      </a>",
"      .) The decline in smoking in younger individuals, particularly males, and increase in women, may be a factor in the declining",
"      <span class=\"nowrap\">",
"       male/female",
"      </span>",
"      ratio of ulcer disease. Smoking does not appear to be a factor in the ulcer complications found in older women or in NSAID-related ulcers.",
"     </li>",
"     <li>",
"      Other factors, such as the extreme psychological stress associated with traumatic events, are associated with a transient increase in ulcer disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3658?source=see_link\">",
"       \"Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Regional and other demographic variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be considerable variation in the rates and pattern of peptic ulcer disease among different regions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/31\">",
"     31",
"    </a>",
"    ]. Unfortunately, there are limited population-based studies to support firm conclusions. A few examples of the available data follow.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of",
"      <em>",
"       H. pylori",
"      </em>",
"      is similar in south and north China. However, review of endoscopic and case records over a 10 year period to identify cases of confirmed duodenal and gastric ulcer and gastric cancer revealed that DU rates were 2.4 times as common in southern as compared to northern China. GU was also more common in southern, compared to northern regions of China, whereas gastric cancer rates were 1.6 times more common in northern regions [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar pattern between the north and south of India has also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/33\">",
"       33",
"      </a>",
"      ]. A review of 20,053 records from patients undergoing endoscopy for dyspepsia and a prospective study of 590 endoscopy patients confirmed these patterns [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/34\">",
"       34",
"      </a>",
"      ]. Furthermore, an endoscopic, population-based survey found 12:1 predominance of DUs over GUs in from a supposedly low ulcer prevalence region of northern region of India [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/35\">",
"       35",
"      </a>",
"      ]. These findings support the existence of regional differences in the pattern of ulcer disease in India.",
"     </li>",
"     <li>",
"      In South Africa, hospital admission rates suggest that the prevalence of DUs is much lower in rural areas, compared to cities [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 13-year review of all surgical procedures for peptic ulcer complications at a Nigerian hospital found that obstruction was the most common complication (56 percent), followed by perforation (30 percent) and bleeding (10 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/37\">",
"       37",
"      </a>",
"      ]. This pattern is the reverse of what is seen in Western countries for unexplained reasons.",
"     </li>",
"     <li>",
"      In Singapore, Indians have a higher prevalence of",
"      <em>",
"       H. pylori",
"      </em>",
"      antibodies but a lower frequency of peptic ulcer than the Chinese [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although",
"    <em>",
"     H. pylori",
"    </em>",
"    is the predominant cause of peptic ulcer disease worldwide, it appears that there are regional differences in prevalence of DUs, GUs, and gastric cancer that are not explained by this infection per se. Patterns of NSAID use and smoking are likely to be important. Some regional differences probably relate to the pattern of",
"    <em>",
"     H. pylori",
"    </em>",
"    -associated gastritis occurring in different regions. Diet has also been hypothesized to account for regional differences (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"     \"Overview of the natural history and treatment of peptic ulcer disease\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peptic ulcer disease is associated with two major factors:",
"    <em>",
"     Helicobacter pylori",
"    </em>",
"    infection; and the consumption of nonsteroidal antiinflammatory drugs (NSAIDs), which are reviewed here briefly and are discussed in greater detail on corresponding topic reviews (",
"    <a class=\"graphic graphic_table graphicRef79691 \" href=\"UTD.htm?4/40/4749\">",
"     table 1",
"    </a>",
"    ). There are also a number of other defined mechanisms for peptic ulcer disease that are much less common but becoming more evident as the prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    declines in developed countries (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link\">",
"     \"Unusual causes of peptic ulcer disease\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Two points are of critical importance in both discussing causes and in evaluating patients with peptic ulcers.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <em>",
"       H. pylori",
"      </em>",
"      can be difficult to diagnose in some patients; false-negative testing is an important consideration. False negative serologic tests occur in at least 10 percent of patients. False negative results are common following use of antibiotics, proton pump inhibitors, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"       bismuth",
"      </a>",
"      in tests that depend upon the bacterial load of",
"      <em>",
"       H. pylori",
"      </em>",
"      . Similarly, acute gastrointestinal bleeding decreases sensitivity of urease testing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"       \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surreptitious NSAID use is surprisingly common in the face of refractory and complicated ulcers [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, when evaluating publications and patients, it is important to exclude falsely-negative",
"    <em>",
"     H. pylori",
"    </em>",
"    status and unrecognized or surreptitious NSAID use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     H. pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    both in the general population and in peptic ulcer patients is decreasing rapidly in developed regions, presumably due to improved hygiene and decreased",
"    <em>",
"     H. pylori",
"    </em>",
"    transmission in early childhood. In regions such as Southern Europe and Japan, where prevalence rates for",
"    <em>",
"     H. pylori",
"    </em>",
"    in both gastric ulcers (GU) and duodenal ulcers (DU) have been over 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/40,41\">",
"     40,41",
"    </a>",
"    ], there is evidence of decreasing",
"    <em>",
"     H. pylori",
"    </em>",
"    prevalence in the population and in peptic ulcer, especially in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/42\">",
"     42",
"    </a>",
"    ]. In regions where this trend is more mature, such as the United States and parts of Europe, the prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    in PUD (with NSAID use excluded) now ranges from 50 to 75 percent and is continuing to fall rapidly [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/43-45\">",
"     43-45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low reinfection rates after",
"    <em>",
"     H. pylori",
"    </em>",
"    cure also mirror the falling",
"    <em>",
"     H. pylori",
"    </em>",
"    prevalence. In contrast, prevalence and reinfection rates remain high in regions where hygiene and socioeconomic conditions have not changed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Within areas where the overall",
"    <em>",
"     H. pylori",
"    </em>",
"    prevalence is dropping rapidly, there are population segments where rates are higher, warranting special consideration in their medical management. Individuals with intellectual or developmental disabilities, for example, have higher rates of",
"    <em>",
"     H. pylori",
"    </em>",
"    infection and much higher rates of",
"    <em>",
"     H. pylori",
"    </em>",
"    recurrence after triple drug treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, impoverished inner city and rural populations generally have much higher",
"    <em>",
"     H. pylori",
"    </em>",
"    prevalence, although this situation also appears to be changing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/47\">",
"     47",
"    </a>",
"    ]. As an example, the prevalence of",
"    <em>",
"     H. pylori",
"    </em>",
"    and peptic ulcer at one institution in West Virginia fell over an 11-year period from 66 percent in 263 patients to 7 percent in 251 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/48\">",
"     48",
"    </a>",
"    ]. In parallel, peptic ulcer prevalence at endoscopy fell from 39 to 6 percent. Although several factors may have influenced this trend, such as pre-endoscopy treatment of",
"    <em>",
"     H. pylori",
"    </em>",
"    and use of antisecretory agents, a substantial decrease in the prevalence of both",
"    <em>",
"     H. pylori",
"    </em>",
"    and peptic ulcer is likely even in rural populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     NSAIDs, including aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs), including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , increase the risk of peptic ulcer disease. The Food and Drug Administration (FDA) estimated that nonselective NSAIDs were associated with a 1 to 4 percent per year risk of a clinically significant NSAID-induced gastrointestinal event, including gastrointestinal bleeding, perforation, or pyloric obstruction. This degree of risk has also been seen in epidemiologic studies and in prospective, controlled trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    has been in use for more than a century, low-dose aspirin for the prevention of thrombotic cardiovascular disease has become an important cause of symptomatic ulcer and of gastrointestinal (GI) complications [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/10,49\">",
"     10,49",
"    </a>",
"    ]. The effects of aspirin are probably dose dependent, especially in the higher dose range; doses of 75 to 300 mg daily cause a two- to threefold increased risk of GI bleeding due both to upper GI ulceration and to lower GI causes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H5#H5\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several factors that influence the risk of PUD in patients taking NSAIDs, the most important of which is a prior history of clinical ulcer disease or ulcer complications. Other risk factors are the dose; duration of action; duration of therapy of the NSAIDs; advanced age of the patient (generally above 75 years); co-therapy with drugs that enhance toxicity, and comorbidity, especially with cardiovascular disease. Genetic predisposition due to polymorphism of cytochrome P450 2C9 may delay the metabolism of several NSAIDs, with a prolonged duration of drug enhancing the ulcerogenic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/50\">",
"     50",
"    </a>",
"    ]. The risk of gastrointestinal complications increases with time but the risk is highest in the early treatment period among those first starting NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some studies have suggested that a subset of patients who develop bleeding complications on NSAIDs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    has pronounced, reversible prolongation of bleeding times while taking these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/51\">",
"     51",
"    </a>",
"    ]. In one report, bleeding times when initially tested were similar in 61 patients with prior GI bleeding compared to 61 matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/52\">",
"     52",
"    </a>",
"    ]. However, 375 mg of aspirin induced an exaggerated prolongation of bleeding time in about 30 percent of patients with a prior history of GI bleeding, compared to only 9 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interactions of NSAIDs with other drugs are critical factors influencing the risk from NSAIDs. Co-therapy of NSAIDs with steroids, anticoagulants, other NSAIDs, low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , selective serotonin reuptake inhibitors (SSRI), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    dramatically increase the risk of ulcer complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-platelet agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    was associated with a 12 month rebleeding rate of 8.6 percent, compared to 0.7 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus a PPI in a study of high-risk patients with a prior history of GI bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/53\">",
"     53",
"    </a>",
"    ]. Thus, clopidogrel is contraindicated in high risk patients when used alone or in combination with NSAIDs. Any anti-platelet agent should be prescribed with caution in patients at risk for ulcer complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     COX-2 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled trials with COX-2 selective inhibitors have demonstrated a reduction in risk of clinical peptic ulcers and their complications [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/54\">",
"     54",
"    </a>",
"    ]. Even though COX-2 inhibitors may have a reduced risk compared to traditional NSAIDs, the risk is increased compared with placebo. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10375?source=see_link\">",
"     \"COX-2 inhibitors and gastroduodenal toxicity &mdash; major clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of a PPI with a COX-2 inhibitor does appear to largely reverse ulcerogenic effects, evident by findings that patients who are at high risk for ulcer complications and require NSAIDS have markedly reduced complication rates when maintained on a COX-2 inhibitor plus a PPI [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence that COX-2 inhibitors alone have advantages over other NSAIDs for patients with unhealed ulcers or during ulcer healing. Since COX-2 inhibitors appear to inhibit healing of peptic ulcers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/56\">",
"     56",
"    </a>",
"    ], they are not an attractive alternative for patients with active peptic ulcer disease. Therefore, NSAIDs, including COX-2 inhibitor, should be stopped during the healing treatment of peptic ulcer. After the healing phase of treatment, if NSAIDs are required, a COX-2 inhibitor should be used in combination with a PPI.",
"   </p>",
"   <p>",
"    Another important point is that low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    has synergistic effects, exacerbating the risk of GI complications caused by both NSAIDs and COX-2 inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .) Co-therapy of low dose aspirin with COX-2 inhibitors, and with at least some nonselective NSAIDs, also attenuates the cardiovascular protective effects of the aspirin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     NSAID-H. pylori synergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interaction between NSAIDs and",
"    <em>",
"     H. pylori",
"    </em>",
"    is controversial and complex (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    ). The confusion is not surprising because",
"    <em>",
"     H. pylori",
"    </em>",
"    causes a spectrum of gastric consequences ranging from antral-predominant gastritis with robust acid secretion that predisposes to duodenal ulcer formation, to pangastritis with achlorhydria, where the peptic ulcer risk is nil. Patients with",
"    <em>",
"     H. pylori",
"    </em>",
"    and low acid secretion may be protected, whereas the subset with active or subclinical ulcer disease would be at high risk from NSAID complications. As noted, 1 to 4 percent of asymptomatic",
"    <em>",
"     H. pylori",
"    </em>",
"    positive subjects without an ulcer history have silent peptic ulcers evident at surveillance endoscopy; presumably this is the group that would be at the highest risk with exposure to NSAIDs.",
"   </p>",
"   <p>",
"    Two meta-analyses of case-controlled studies have found synergism between",
"    <em>",
"     H. pylori",
"    </em>",
"    and NSAIDs in producing both peptic ulcer and ulcer bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Such studies establish an association, but not causality. Much more convincing evidence for the impact of",
"    <em>",
"     H. pylori",
"    </em>",
"    on NSAID-induced ulcer formation and complications comes from controlled trials studying primary prevention in which patients who required NSAIDs and were",
"    <em>",
"     H. pylori",
"    </em>",
"    positive were randomized before starting NSAIDs to an active or placebo",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. The first trial treated all patients with NSAIDs for eight weeks; endoscopic ulcers were found in 26 percent of patients with persistent",
"    <em>",
"     H. pylori",
"    </em>",
"    and 3 percent with successful eradication [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/59\">",
"     59",
"    </a>",
"    ]. A second trial entered a higher risk group with a history of dyspepsia or prior ulcer and followed them for six months on NSAIDs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/60\">",
"     60",
"    </a>",
"    ]. Endoscopic ulcers were found in 34 percent of the control group compared to 12 percent of the eradication group; importantly, complicated ulcers were reduced from 27 percent in the control group to 4 percent in the eradication group.",
"   </p>",
"   <p>",
"    In contrast to these studies with NSAID-na&iuml;ve patients, curing",
"    <em>",
"     H. pylori",
"    </em>",
"    in patients who are already taking NSAIDs has much less benefit for reducing endoscopic ulceration and ulcer complications. As an example, in one controlled trial",
"    <em>",
"     H. pylori",
"    </em>",
"    positive patients with a history of prior NSAID-associated ulcer bleeding were randomized to eradication or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    treatment. During the subsequent six months of treatment with conventional NSAIDs, complications occurred in 24 percent in patients randomized to eradication therapy versus 4 percent in patients treated with continuous PPI co-therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/62\">",
"     62",
"    </a>",
"    ]. Other studies confirm that ulcer recurrence rates upon resuming NSAIDs are higher with",
"    <em>",
"     H. pylori",
"    </em>",
"    cure alone compared to PPI co-therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although available data are conflicting, the situation may be different for low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . The study referenced above [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/62\">",
"     62",
"    </a>",
"    ] also included patients with a prior ulcer bleed who were treated with low dose aspirin for six months following",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication; recurrent bleeding occurred in 1.9 percent of this group compared to 0.9 percent in patients also treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    co-therapy. However, another similar study found a considerably higher recurrent ulcer complication rate during low dose aspirin treatment with",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication alone compared with a group also treated with PPI co-therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/63\">",
"     63",
"    </a>",
"    ]. However, interpretation of this study is limited because, of the nine patients with recurrent complications following eradication treatment, four still had",
"    <em>",
"     H. pylori",
"    </em>",
"    infection and two were using other NSAIDs.",
"   </p>",
"   <p>",
"    Four consensus panels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19113/abstract/65-68\">",
"     65-68",
"    </a>",
"    ] have interpreted available data as convincing evidence for",
"    <em>",
"     H. pylori",
"    </em>",
"    -NSAID synergy and for the importance of testing and treating",
"    <em>",
"     H. pylori",
"    </em>",
"    before starting NSAIDs at least in high risk patients, such as older patients, those with serious comorbidity, dyspepsia, or a history of prior ulcer disease. Even though there are no definitive studies directly testing primary prevention for low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , similar synergy with",
"    <em>",
"     H. pylori",
"    </em>",
"    in inducing complicated ulcers and benefit from curing",
"    <em>",
"     H. pylori",
"    </em>",
"    before starting aspirin can be anticipated. Since there are several potential benefits to curing",
"    <em>",
"     H. pylori",
"    </em>",
"    infection, we favor testing for and treating",
"    <em>",
"     H. pylori",
"    </em>",
"    or at least offering patients this option before initiating NSAIDs or low dose aspirin. Despite the benefits of curing",
"    <em>",
"     H. pylori",
"    </em>",
"    before starting NSAID or low dose aspirin treatment, high risk patients still warrant measures to reduce risk, as considered elsewhere in detail. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reasons for the superior benefit of",
"    <em>",
"     H. pylori",
"    </em>",
"    eradication in na&iuml;ve versus prior NSAID users have not been elucidated. A major candidate is the reduction of patients with",
"    <em>",
"     H. pylori",
"    </em>",
"    -induced subclinical ulcers or an ulcer diathesis, who probably account for many of the early complications following initiation of NSAID or low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26673836\">",
"    <span class=\"h2\">",
"     Non-NSAID, non-H. pylori ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although some NSAID-negative,",
"    <em>",
"     H. pylori",
"    </em>",
"    -negative ulcers are due to specific causes, such as gastrinoma or viral infections, others remain in the idiopathic category. It is controversial whether non-NSAID, non-",
"    <em>",
"     H. pylori",
"    </em>",
"    ulcers are becoming more prevalent, or just more apparent as the rate of",
"    <em>",
"     H. pylori",
"    </em>",
"    ulcers falls. It is also controversial whether these ulcers have a poor relative outcome, or whether a poor apparent outcome is due to association with other diseases, which cause the poor outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link\">",
"     \"Unusual causes of peptic ulcer disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=see_link\">",
"       \"Patient information: Peptic ulcers (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=see_link\">",
"       \"Patient information: H. pylori infection (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/46/1763?source=see_link\">",
"       \"Patient information: Gastritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=see_link\">",
"       \"Patient information: Peptic ulcer disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"       \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peptic ulcer disease is associated with two major factors:",
"      <em>",
"       Helicobacter pylori",
"      </em>",
"      infection and the consumption of nonsteroidal antiinflammatory drugs (NSAIDs). There are also a number of other defined mechanisms for peptic ulcer that are much less common but becoming more evident as the prevalence of",
"      <em>",
"       H. pylori",
"      </em>",
"      declines in developed countries (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link\">",
"       \"Unusual causes of peptic ulcer disease\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Estimates of the annual incidence of peptic ulcer range from 0.1 to 0.3 percent. The ulcer incidence in",
"      <em>",
"       H. pylori",
"      </em>",
"      -infected individuals is about 1 percent per year, a rate that is 6- to 10-fold higher than for uninfected subjects. Ulcer incidence increases with age for both duodenal and gastric ulcers. Duodenal ulcers emerge two decades earlier than gastric ulcers, particularly in males. The prevalence of peptic ulcer in Western countries appears to have shifted over the second half of the 20",
"      <sup>",
"       th",
"      </sup>",
"      century from being a disease predominant in males to one with a nearly comparable prevalence in both sexes. This pattern may not apply to Asian countries, where duodenal ulcers may still be predominant in males.",
"     </li>",
"     <li>",
"      The trends in peptic ulcer mortality in Europe and the United States followed a birth-cohort phenomenon. Mortality was highest in people born in the second half of the 19",
"      <sup>",
"       th",
"      </sup>",
"      century and has fallen steadily in the generations born since the beginning of the 20",
"      <sup>",
"       th",
"      </sup>",
"      century. The decline in",
"      <em>",
"       H. pylori",
"      </em>",
"      prevalence over the 20",
"      <sup>",
"       th",
"      </sup>",
"      century is a major factor underlying the fall in ulcer prevalence and mortality. However, other still undefined factors are also at play. In light of these longer range trends, rates of hospitalization and death from peptic ulcer, emergency admissions for ulcer complications do appear to be falling after having been relatively stable for the past two decades.",
"     </li>",
"     <li>",
"      Even within a generally low prevalence region,",
"      <em>",
"       H. pylori",
"      </em>",
"      infection and its complications remain somewhat higher in certain predisposed populations, such as impoverished inner city populations, and in individuals whose hygiene and self care are compromised by factors such as intellectual or developmental disabilities. Reinfection is also likely to be higher in such populations.",
"     </li>",
"     <li>",
"      Several factors predict increased risk with NSAIDs, such as",
"      <em>",
"       H. pylori",
"      </em>",
"      infection, advanced age, comorbidities, and co-therapy with drugs such as corticosteroids, anticoagulants, and bisphosphonates. Evidence especially in na&iuml;ve NSAID or low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      users indicates synergy with",
"      <em>",
"       H. pylori",
"      </em>",
"      and justifies testing for",
"      <em>",
"       H. pylori",
"      </em>",
"      before first starting NSAIDs or low dose aspirin treatment. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/1\">",
"      Sonnenberg A, Everhart JE. Health impact of peptic ulcer in the United States. Am J Gastroenterol 1997; 92:614.",
"     </a>",
"    </li>",
"    <li>",
"     Cruveilhier J. Maladies de l'estomac. In: de l'Anatomie Pathologique du Corps Humain, Bailliere, Paris 1835.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/3\">",
"      Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 2007; 132:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/4\">",
"      Graham DY. Changing patterns of peptic ulcer, gastro-oesophageal reflux disease and Helicobacter pylori: a unifying hypothesis. Eur J Gastroenterol Hepatol 2003; 15:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/5\">",
"      Hu PJ, Li YY, Lin HL, et al. Gastric atrophy and regional variation in upper gastrointestinal disease. Am J Gastroenterol 1995; 90:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/6\">",
"      Burstein M, Monge E, Le&oacute;n-Bar&uacute;a R, et al. Low peptic ulcer and high gastric cancer prevalence in a developing country with a high prevalence of infection by Helicobacter pylori. J Clin Gastroenterol 1991; 13:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/7\">",
"      Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology 1997; 113:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/8\">",
"      Valle J, Kekki M, Sipponen P, et al. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol 1996; 31:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/9\">",
"      Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 1995; 9 Suppl 2:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/10\">",
"      Garc&iacute;a Rodr&iacute;guez LA, Hern&aacute;ndez-D&iacute;az S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 2004; 159:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/11\">",
"      Kurata JH. Epidemiology: Peptic ulcer risk factors. Semin Gastrointest Dis 1993; 4:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/12\">",
"      Rosenstock SJ, J&oslash;rgensen T, Bonnevie O, Andersen LP. Does Helicobacter pylori infection explain all socio-economic differences in peptic ulcer incidence? Genetic and psychosocial markers for incident peptic ulcer disease in a large cohort of Danish adults. Scand J Gastroenterol 2004; 39:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/13\">",
"      Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009; 29:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/14\">",
"      Sonnenberg A. Temporal trends and geographical variations of peptic ulcer disease. Aliment Pharmacol Ther 1995; 9 Suppl 2:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/15\">",
"      Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9 Suppl 2:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/16\">",
"      Sipponen P, Varis K, Fr&auml;ki O, et al. Cumulative 10-year risk of symptomatic duodenal and gastric ulcer in patients with or without chronic gastritis. A clinical follow-up study of 454 outpatients. Scand J Gastroenterol 1990; 25:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/17\">",
"      Anand BS, Raed AK, Malaty HM, et al. Low point prevalence of peptic ulcer in normal individuals with Helicobacter pylori infection. Am J Gastroenterol 1996; 91:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/18\">",
"      Akdamar K, Ertan A, Agrawal NM, et al. Upper gastrointestinal endoscopy in normal asymptomatic volunteers. Gastrointest Endosc 1986; 32:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/19\">",
"      Kaneko E, Ooi S, Ito G, Honda N. Natural history of duodenal ulcer detected by the gastric mass surveys in men over 40 years of age. Scand J Gastroenterol 1989; 24:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/20\">",
"      Bernersen B, Johnsen R, Straume B, et al. Towards a true prevalence of peptic ulcer: the S&oslash;rreisa gastrointestinal disorder study. Gut 1990; 31:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/21\">",
"      Aro P, Storskrubb T, Ronkainen J, et al. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol 2006; 163:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/22\">",
"      el-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/23\">",
"      Bardhan KD, Williamson M, Royston C, Lyon C. Admission rates for peptic ulcer in the trent region, UK, 1972--2000. changing pattern, a changing disease? Dig Liver Dis 2004; 36:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/24\">",
"      Primatesta P, Goldacre MJ, Seagroatt V. Changing patterns in the epidemiology and hospital care of peptic ulcer. Int J Epidemiol 1994; 23:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/25\">",
"      Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut 2002; 50:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/26\">",
"      Kang JY, Elders A, Majeed A, et al. Recent trends in hospital admissions and mortality rates for peptic ulcer in Scotland 1982-2002. Aliment Pharmacol Ther 2006; 24:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/27\">",
"      Post PN, Kuipers EJ, Meijer GA. Declining incidence of peptic ulcer but not of its complications: a nation-wide study in The Netherlands. Aliment Pharmacol Ther 2006; 23:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/28\">",
"      Manuel D, Cutler A, Goldstein J, et al. Decreasing prevalence combined with increasing eradication of Helicobacter pylori infection in the United States has not resulted in fewer hospital admissions for peptic ulcer disease-related complications. Aliment Pharmacol Ther 2007; 25:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/29\">",
"      Wang YR, Richter JE, Dempsey DT. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006. Ann Surg 2010; 251:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/30\">",
"      Sadic J, Borgstr&ouml;m A, Manjer J, et al. Bleeding peptic ulcer - time trends in incidence, treatment and mortality in Sweden. Aliment Pharmacol Ther 2009; 30:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/31\">",
"      Lam SK. Differences in peptic ulcer between East and West. Baillieres Best Pract Res Clin Gastroenterol 2000; 14:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/32\">",
"      Wong BC, Ching CK, Lam SK, et al. Differential north to south gastric cancer-duodenal ulcer gradient in China. China Ulcer Study Group. J Gastroenterol Hepatol 1998; 13:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/33\">",
"      Tovey F. Peptic ulcer in India and Bangladesh. Gut 1979; 20:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/34\">",
"      Tovey FI, Hobsley M, Kaushik SP, et al. Duodenal gastric metaplasia and Helicobacter pylori infection in high and low duodenal ulcer-prevalent areas in India. J Gastroenterol Hepatol 2004; 19:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/35\">",
"      Singh V, Trikha B, Nain CK, et al. Epidemiology of Helicobacter pylori and peptic ulcer in India. J Gastroenterol Hepatol 2002; 17:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/36\">",
"      Tovey FI, Hobsley M, Segal I, Jayaraj AP. Duodenal ulcer in South Africa: home-pounded versus milled maize. J Gastroenterol Hepatol 2005; 20:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/37\">",
"      Irabor DO. An audit of peptic ulcer surgery in Ibadan, Nigeria. West Afr J Med 2005; 24:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/38\">",
"      Kang JY, Yeoh KG, Ho KY, et al. Racial differences in Helicobacter pylori seroprevalence in Singapore: correlation with differences in peptic ulcer frequency. J Gastroenterol Hepatol 1997; 12:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/39\">",
"      Hirschowitz BI, Lanas A. Atypical and aggressive upper gastrointestinal ulceration associated with aspirin abuse. J Clin Gastroenterol 2002; 34:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/40\">",
"      Arroyo MT, Forne M, de Argila CM, et al. The prevalence of peptic ulcer not related to Helicobacter pylori or non-steroidal anti-inflammatory drug use is negligible in southern Europe. Helicobacter 2004; 9:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/41\">",
"      Nishikawa K, Sugiyama T, Kato M, et al. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol 2000; 12:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/42\">",
"      P&eacute;rez-Aisa MA, Del Pino D, Siles M, Lanas A. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther 2005; 21:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/43\">",
"      Ciociola AA, McSorley DJ, Turner K, et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol 1999; 94:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/44\">",
"      Jyotheeswaran S, Shah AN, Jin HO, et al. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol 1998; 93:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/45\">",
"      Chiorean MV, Locke GR 3rd, Zinsmeister AR, et al. Changing rates of Helicobacter pylori testing and treatment in patients with peptic ulcer disease. Am J Gastroenterol 2002; 97:3015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/46\">",
"      Kitchens DH, Binkley CJ, Wallace DL, Darling D. Helicobacter pylori infection in people who are intellectually and developmentally disabled: a review. Spec Care Dentist 2007; 27:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/47\">",
"      Kalaghchi B, Mekasha G, Jack MA, Smoot DT. Ideology of Helicobacter pylori prevalence in peptic ulcer disease in an inner-city minority population. J Clin Gastroenterol 2004; 38:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/48\">",
"      McJunkin B, Sissoko M, Levien J, et al. Dramatic decline in prevalence of Helicobacter pylori and peptic ulcer disease in an endoscopy-referral population. Am J Med 2011; 124:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/49\">",
"      Garc&iacute;a Rodr&iacute;guez LA, Hern&aacute;ndez-D&iacute;az S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 2001; 52:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/50\">",
"      Pilotto A, Seripa D, Franceschi M, et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 2007; 133:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/51\">",
"      Day JP, Lanas A, Rustagi P, Hirschowitz BI. Reversible prolonged skin bleeding time in acute gastrointestinal bleeding presumed due to NSAIDs. J Clin Gastroenterol 1996; 22:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/52\">",
"      Lanas AI, Arroyo MT, Esteva F, et al. Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use. Gut 1996; 39:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/53\">",
"      Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/54\">",
"      Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/55\">",
"      Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/56\">",
"      Perini RF, Ma L, Wallace JL. Mucosal repair and COX-2 inhibition. Curr Pharm Des 2003; 9:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/57\">",
"      Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/58\">",
"      Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol 2006; 4:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/59\">",
"      Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/60\">",
"      Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/61\">",
"      Labenz J, Blum AL, Bolten WW, et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002; 51:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/62\">",
"      Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/63\">",
"      Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/64\">",
"      Vergara M, Catal&aacute;n M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/65\">",
"      Lanza FL, Chan FK, Quigley EM, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/66\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008; 103:2890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/67\">",
"      Fischbach W, Malfertheiner P, Hoffmann JC, et al. S3-guideline \"helicobacter pylori and gastroduodenal ulcer disease\" of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. Z Gastroenterol 2009; 47:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19113/abstract/68\">",
"      Rostom A, Moayyedi P, Hunt R, Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009; 29:481.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 22 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19113=[""].join("\n");
var outline_f18_42_19113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H116189959\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Trends in prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Regional and other demographic variation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      H. pylori",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      NSAIDs, including aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - COX-2 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NSAID-H. pylori synergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26673836\">",
"      Non-NSAID, non-H. pylori ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/22\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/22|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/37/11871\" title=\"picture 1\">",
"      Duodenal ulcer Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/22|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/40/4749\" title=\"table 1\">",
"      Causes of peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=related_link\">",
"      Association between Helicobacter pylori infection and duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/16/43271?source=related_link\">",
"      Bacteriology and epidemiology of Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10375?source=related_link\">",
"      COX-2 inhibitors and gastroduodenal toxicity &mdash; major clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40282?source=related_link\">",
"      Overview of the complications of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=related_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/46/1763?source=related_link\">",
"      Patient information: Gastritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=related_link\">",
"      Patient information: H. pylori infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/60/964?source=related_link\">",
"      Patient information: Peptic ulcer disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=related_link\">",
"      Patient information: Peptic ulcers (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3658?source=related_link\">",
"      Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=related_link\">",
"      Unusual causes of peptic ulcer disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_42_19114="Pathogenesis of osteoarthritis";
var content_f18_42_19114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of osteoarthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/42/19114/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/42/19114/contributors\">",
"     Kenneth C Kalunian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/42/19114/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/42/19114/contributors\">",
"     Peter Tugwell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/42/19114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/42/19114/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/42/19114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoarthritis results from articular cartilage failure induced by a complex interplay of genetic, metabolic, biochemical, and biomechanical factors with secondary components of inflammation. The process involves interactive degradation and repair processes of cartilage, bone, and synovium.",
"   </p>",
"   <p>",
"    Chondrocytes are probably the most important cells responsible for the development of the osteoarthritic process. Human and animal studies indicate that chondrocytes exhibit numerous abnormal metabolic features as part of the osteoarthritis process. These include increased levels of proliferative [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], synthetic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], and degradative activity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the abnormal physiologic responses observed in osteoarthritis cannot be reproduced by any single purified cellular factor. It is, therefore, likely that a combination of factors present in the joint result in multiple metabolic alterations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/7\">",
"     7",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monocyte-derived peptides may induce increased chondrocyte proliferative activity and matrix degradation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/8-11\">",
"       8-11",
"      </a>",
"      ]. Other growth factors also stimulate chondrocyte synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cartilage fragments and soluble proteoglycan and type II collagen have been demonstrated in the synovial fluid of osteoarthritic joints [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/14-17\">",
"       14-17",
"      </a>",
"      ]. These cartilage degradative products can stimulate the release of inflammatory mediators from macrophages [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/18-20\">",
"       18-20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the pathogenesis of osteoarthritis. The risk factors associated with this disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=see_link\">",
"     \"Risk factors for and possible causes of osteoarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two principal mechanisms are thought to initiate osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In most patients, the initiating mechanism is damage to normal articular cartilage by physical forces, which can be either single events of macrotrauma or repeated microtrauma [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/22\">",
"       22",
"      </a>",
"      ]. Chondrocytes react to this injury by releasing degradative enzymes and by elaborating inadequate repair responses [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/22-25\">",
"       22-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Less commonly, fundamentally defective cartilage initially fails under normal joint loading, thereby leading to osteoarthritis. Examples include a type II collagen gene defect or ochronotic cartilage that fails because of deleterious pigment deposition [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initiation of the osteoarthritic process, therefore, appears to involve abnormalities in biomechanical forces",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cartilage. Once begun, the pathway leading to osteoarthritis involves numerous other factors. These include mechanotransduction; the interplay between proteases, protease inhibitors, and cytokines on cartilage degradation and on the mechanisms of cartilage repair; and the contributions from multiple risk factors (such as obesity, aging, mineral deposition, systemic hormones, and abnormalities in neurogenic control).",
"   </p>",
"   <p>",
"    Abnormalities associated with osteoarthritis are not restricted to the articular cartilage. Thickening of the subchondral bone (sclerosis) is a classic radiographic feature, and magnetic resonance imaging has revealed abnormalities in the juxtaarticular bone marrow that correlate with the presence of a relatively increased bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETIC PREDISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of genetic studies, ranging from OA prevalence in twins and other siblings, and whole genome scanning techniques suggests that there is a genetic contribution to the risk of developing OA. This genetic aspect of the pathogenesis of OA is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=see_link&amp;anchor=H24#H24\">",
"     \"Risk factors for and possible causes of osteoarthritis\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EXERCISE AND MECHANICAL LOADING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interaction between exercise and osteoarthritis of the weight-bearing joints is complex. In vitro, in vivo, and clinical data suggest that, in various forms and degrees, exercise may prevent, cause, accelerate, or treat osteoarthritis.",
"   </p>",
"   <p>",
"    In general, studies in (human) runners have failed to demonstrate an increased risk for osteoarthritis of the knee. This evidence is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=see_link&amp;anchor=H24287198#H24287198\">",
"     \"Overview of running injuries of the lower extremity\", section on 'Knee OA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether the direct effect of exercise or mechanical loading is beneficial or detrimental to the health of weight-bearing cartilage (an avascular and aneural tissue) likely relates to the magnitude and duration of the physical stimulus that is sensed by the chondrocytes within that cartilage. These applied external stresses are modified by several factors including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The integrity of the extracellular matrix [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The strength and reflex activation of supporting muscle groups [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The proprioceptive system of the involved extremity [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/31\">",
"       31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The relative stiffness of the subchondral bone",
"     </li>",
"     <li>",
"      The presence of any abnormalities of alignment (eg, genu varus or genu valgus) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/32\">",
"       32",
"      </a>",
"      ] or structure (eg, ligamentous laxity or absence of meniscus) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect on chondrocytes and matrix",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous in vitro models have explored the relationship between repetitive, mechanical loading and resultant changes in cellular function and matrix elements. Chondrocytes are clearly sensitive to mechanical forces. As an example, chondrocyte production of the macromolecular extracellular matrix components is dependent upon both the load magnitude (which is modified by the integrity of the collagen meshwork) and frequency (which is altered by the matrix proteoglycan concentration) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, two studies have found a significant increase in matrix macromolecule synthesis at frequencies of loading (0.1 Hz) which approximate those generated by normal walking [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In vitro data generally support an \"inverted-U\"-shaped relationship between the magnitude or duration of loading and the resultant matrix macromolecule production.",
"   </p>",
"   <p>",
"    The mechanism by which cells convert mechanical stimuli into a biochemical signal has been termed mechanotransduction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/36\">",
"     36",
"    </a>",
"    ]. Although great strides have been made toward understanding this process in cardiac myocytes and endothelial cells, only recently has attention been focused upon the chondrocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/29\">",
"     29",
"    </a>",
"    ]. As a result, the process of mechanotransduction with respect to this cell is poorly understood at present. Research in mechanotransduction seeks in part to identify the relative contributions of several candidate cellular structures as mechanotransducers responsible for alterations in cell behavior, including macromolecule synthesis in the chondrocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/29,37\">",
"     29,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differences in the responses to repetitive loading of cultured chondrocytes from healthy and osteoarthritic cartilage have been noted. As an example, a transient increase and decrease in levels of mRNA for aggrecan and metalloproteinase 3, respectively, were measured by semiquantitative polymerase chain reaction in chondrocytes derived from normal human cartilage that were grown on a solid support and subjected to repetitive loading [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/38\">",
"     38",
"    </a>",
"    ]. In comparison, there was no change in mRNA levels for these proteins in cells cultured from osteoarthritic cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/38\">",
"     38",
"    </a>",
"    ]. Although mechanotransduction by cultured chondrocytes from normal cartilage has been ascribed to integrins, stretch-activated ion channels, and an",
"    <span class=\"nowrap\">",
"     autocrine/paracrine",
"    </span>",
"    effect of interleukin-4, there is at present no explanation for the apparent difference in mechanotransduction in chondrocytes cultivated from sufferers of osteoarthritis.",
"   </p>",
"   <p>",
"    The role of the chondrocyte in the pathogenesis of lumbar disc degeneration was studied using autopsy material from 47 individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/39\">",
"     39",
"    </a>",
"    ]. Phenotypic alterations of chondrocytes (as monitored by Type IV collagen deposition in young adults with minor lesions and Type X collagen deposition in advanced lesions) suggested distinct cellular reactions possibly due to enhanced oxidative stresses. The immunolocalization of N-(carboxymethyl)lysine (CML), a biomarker for oxidative stress, correlated with the degree of oxidative stress. The staining pattern indicated that the discs undergo accumulative stress, leading to altered properties of the collagen fibrils and, then, tissue destruction. The deposition of CML proved to be the best marker for ongoing age-related changes in the intervertebral disc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Effect on cartilage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with normal cartilage, cartilage from osteoarthritic tissue deforms more readily in response to the same load and more fluid is lost during the application of a given load [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/40\">",
"     40",
"    </a>",
"    ]. The same external load therefore results in different mechanical stimuli in normal and osteoarthritic cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Such alterations in cartilage biomechanics may change the",
"    <strong>",
"     perception",
"    </strong>",
"    of normal mechanical loads (which are required for the maintenance of healthy, articular cartilage) into pathologically larger loads of longer duration (which are damaging to the articular cartilage) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/41\">",
"     41",
"    </a>",
"    ]. Useful therapeutic interventions in osteoarthritis may therefore use pharmaceuticals which modify the magnitude of the biochemical signaling in response to mechanical loading.",
"   </p>",
"   <p>",
"    One report reviewed the animal studies in several species which investigated the risk of developing cartilage changes after alterations in physical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/42\">",
"     42",
"    </a>",
"    ]. Several studies have found an increased risk of osteoarthritis in specific joints after increased mechanical loading. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The hips and shoulders of huskies exposed to sled pulling",
"     </li>",
"     <li>",
"      The knees of guinea pigs engaged in running",
"     </li>",
"     <li>",
"      The forelegs of horses who race (run)",
"     </li>",
"     <li>",
"      The knees of rabbits exposed to impact joint loading",
"     </li>",
"     <li>",
"      The forelegs of tigers and lions after prolonged springing and running",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, some studies failed to identify similar increases in risk of osteoarthritis with increased loading, including those which assessed the knees of sheep ambulating on cement surfaces, and the knees of rabbits exposed to running exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more detailed knowledge of the impact of physical activity on cartilage morphology and biochemical content has been achieved regarding running exercise in dogs. Progressive structural changes in cartilage have been noted ranging from increases in cartilage thickness, stiffness, and proteoglycan content seen with moderate running [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/43\">",
"     43",
"    </a>",
"    ], to decreased cartilage thickness and stiffness with increasingly more strenuous running [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/44\">",
"     44",
"    </a>",
"    ], and, finally, to subchondral bone remodeling after chronic, strenuous running [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/45\">",
"     45",
"    </a>",
"    ]. Importantly, none of these studies revealed fibrillation or erosion of the articular surfaces and, thus, have been interpreted as reflecting adaptations to a high load environment rather than evidence of osteoarthritis.",
"   </p>",
"   <p>",
"    A sufficient degree of joint loading appears to be a critical factor for cartilage health since similar changes in articular cartilage have been observed with experimental disuse atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/41\">",
"     41",
"    </a>",
"    ]. As an example, the removal of load bearing forces by casting the limbs of animals with nonrigid fixation has led to several deleterious effects which were reversible with remobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/46\">",
"     46",
"    </a>",
"    ]. These changes include reduced proteoglycan content and synthesis, increased metalloproteinase levels with decreased tissue inhibitor of metalloproteinase (TIMP) levels, and decreased cartilage thickness and stiffness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, experimental amputation results in thinning of the cartilage in the joint proximal to the severed portion of the limb despite its regular movement [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/47\">",
"     47",
"    </a>",
"    ]. In contrast, experimental loading of porcine articular cartilage results in increased secretion of TIMP, a process that may be mediated by basic fibroblast growth factor [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Exercise and muscle weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weakness of the quadriceps group may be etiologically related to the initiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression of osteoarthritis of the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=see_link\">",
"     \"Risk factors for and possible causes of osteoarthritis\"",
"    </a>",
"    .) The mechanism favoring the development of osteoarthritis may include a deficit in deceleration of the leg during the terminal portion of the swing phase of gait [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/51\">",
"     51",
"    </a>",
"    ], thereby creating an increased heel-strike transient which is transmitted to the knee as an increase in contact force [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/30\">",
"     30",
"    </a>",
"    ]. A randomized, placebo-controlled trial of quadriceps strengthening exercises is needed to establish whether or not this intervention can prevent the development or progression of the pathologic changes of osteoarthritis, or the associated joint pain and disability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Exercise and proprioceptive defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unilateral osteoarthritis have been shown to bear bilateral deficits of proprioception at the knee, even in the setting of unilateral osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/52\">",
"     52",
"    </a>",
"    ]. Proprioceptive deficits may slow protective periarticular muscular reflexes and, therefore, increase the risk to cartilage integrity imposed by mechanical loads, particularly rapidly applied loads which circumvent the load absorbing capabilities of the muscles supporting the joint [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/31,53\">",
"     31,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Altered proprioception may contribute to osteoarthritis by another mechanism in a subset of patients. Through a process termed \"arthrogenous muscle inhibition,\" abnormal afferent input from the osteoarthritic knees is thought to cause an abnormal efferent signal to the quadriceps group, and contribute to the insufficient activity of that muscle group [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mechanical loads and internal derangements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two notable animal models have identified the increased risk for osteoarthritis imposed by internal derangement to structures of the knee. The rabbit partial meniscectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/55\">",
"     55",
"    </a>",
"    ] and the canine anterior cruciate ligament (ACL) deficient [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/56\">",
"     56",
"    </a>",
"    ] models have revealed predictable changes which are pathologically identical to those seen in osteoarthritis. These changes include a sequential increase in water content, followed by alteration in the quantitative and qualitative production of proteoglycans (with resultant softening of the articular cartilage), which is followed by fibrillation and focal ulceration. In dogs, a dramatic acceleration in the rate of progression to end-stage osteoarthritis can be created by the combination of ACL transection and ipsilateral L4 -S1 dorsal root ganglionectomy; the latter abrogates proprioceptive input [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/57\">",
"     57",
"    </a>",
"    ]. The combination of ligamentous instability and reduction of proprioceptive sensation is thought to result in accelerated osteoarthritis by increasing the forces transmitted to the weight-bearing cartilage of the knee through a maladaptive increase in leg extension at touchdown [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several influences inside and outside of a weight-bearing joint may therefore considerably alter the impact created by a given activity or exercise prior to its perception by the chondrocytes within that joint. Further research is needed to provide a greater understanding of these stress modifying factors including methods to quantify each of them and to weigh their relative importance before evaluation is possible of the risk of osteoarthritis imposed by a given exercise to a given patient. Finally, prospective, controlled trials of exercise versus equivalent medical attention which use arthroscopic change from baseline as the primary outcome measurement are needed to provide direct visualization of the impact of exercise on cartilage integrity in both those at risk for osteoarthritis and those with early osteoarthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROTEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metalloproteases are a class of zinc-containing enzymes which are active in the degradation of cartilage. These enzymes are felt to be",
"    <strong>",
"     key",
"    </strong>",
"    elements in the degradation of cartilage and development of osteoarthritis.",
"   </p>",
"   <p>",
"    Metalloprotease enzymes may be categorized into three main groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Collagenase",
"     </li>",
"     <li>",
"      Stromelysin",
"     </li>",
"     <li>",
"      Gelatinase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each is active in the degradation of cartilage and the development of osteoarthritis. These enzymes are inhibited by tissue inhibitors of metalloproteases (TIMPs). When the ratio of these two groups of balancing proteins is altered, the catabolic metalloproteases become active and enhance cartilage destruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Collagenase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Collagenases are a family of enzymes known to cleave helical type 2 cartilage at a single proteolytic site approximately three quarters from the amino acid terminus at a site characterized by Gly-(Leu or Ile) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/58\">",
"     58",
"    </a>",
"    ]. They also have activity against type X cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/59\">",
"     59",
"    </a>",
"    ]. Collagenases are at low or undetectable levels in normal cartilage, but are increased in osteoarthritic joints. Collagenase-1 (MMP-1), collagenase-2 (MMP-8), and collagenase-3 (MMP-13) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/60\">",
"     60",
"    </a>",
"    ] are thought to be the predominant, active members of this metalloprotein subgroup and are instrumental in cartilage breakdown. Other proteases are responsible for further degradation of the byproducts. The activation of these enzymes may be via interleukin-1, and other cytokines derived in part from chondrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stromelysin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stromelysin (MMP-3) is found in increased levels in osteoarthritic knees in canine models. It has been located predominantly in the synovial cells, but also to a lesser extent in synovial fibroblasts, infiltrating mononuclear cells, and vascular smooth muscle and endothelial cells. The action of this metalloprotease is to activate collagenase&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/63\">",
"     63",
"    </a>",
"    ], and degrade collagen byproducts and type IX collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gelatinase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gelatinase A (MMP-2) is a metalloprotease known to cleave type 1 cartilage. This enzyme is present in osteoarthritic cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/65\">",
"     65",
"    </a>",
"    ]. The exact role of this enzyme in cartilage degradation remains unclear.",
"   </p>",
"   <p>",
"    Metalloproteinases 1, 2, 3, 8, 9, and 13 are present in the superficial portion of osteoarthritic cartilage, and colocalize with proinflammatory cytokines near clustered chondrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/66\">",
"     66",
"    </a>",
"    ]. These enzymes are more difficult to demonstrate in deeper layers of osteoarthritic cartilage and generally cannot be demonstrated by immunohistochemical means in normal human cartilage.",
"   </p>",
"   <p>",
"    Tissue inhibitors of metalloproteinases (TIMPs) are produced by connective tissue cells, and, as mentioned above, current theory suggests that an imbalance between the level of these inhibitors and the metalloproteases leads to an overall catabolic effect and cartilage degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/67\">",
"     67",
"    </a>",
"    ]. These proteins may therefore be found in relative high or low levels and still be suboptimal for metalloprotease inhibition, depending upon the amount of metalloprotease present in the synovium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other proteases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasminogen is the proenzyme of plasmin, which is believed to activate collagenase and lead to cartilage destruction. Plasminogen levels are increased in parallel with those of interleukin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/68\">",
"     68",
"    </a>",
"    ] and collagenase levels are known to increase with increased levels of plasmin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/69\">",
"     69",
"    </a>",
"    ]. As a result, circumstantial evidence supports the role of plasminogen in osteoarthritis development via its activation of other catabolic enzymes.",
"   </p>",
"   <p>",
"    Although its role in the pathogenesis of osteoarthritis is unclear, mRNA for the metalloprotease metargidin (MDC15, ADAM-15) is upregulated in chondrocytes from osteoarthritic cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/70\">",
"     70",
"    </a>",
"    ]. Chondrosarcomas also have increased metargidin mRNA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CYTOKINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elucidating the role of cytokines in the development of osteoarthritis offers some of the greatest potential in altering the incidence and progression of this disease. Recent studies have found these substances in various forms of arthritis and have begun to define their function in the maintenance and degradation of cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. Cytokines act via autocrine and endocrine functions to alter cartilage homeostasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Catabolic cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin-1 (IL-1) is perhaps the best characterized cytokine involved in cartilage degradation. It is synthesized by chondrocytes and mononuclear cells lining the synovium. This compound acts in multiple pathways to suppress synthesis of type 2 (articular) cartilage and promote formation of type 1 (fibrous) cartilage. In addition, interleukin-1 induces catabolic enzymes (eg, stromelysin and collagenase), and suppresses prostaglandin synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/72,74,75\">",
"     72,74,75",
"    </a>",
"    ]. When given in an animal model, intraarticular IL-1 precipitated cartilage damage via proteoglycan loss. In an in vitro model utilizing cultured chondrocytes, the effects of moderate amounts of mechanical strain produced effects that were similar to those caused by exposure to IL-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The level of IL-1 and cell sensitivity to this cytokine are increased in osteoarthritis, thereby leading to enhanced catabolism of cartilage. Clinical studies have demonstrated that IL-1 levels are increased in patients with knee osteoarthritis versus those without arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/77\">",
"     77",
"    </a>",
"    ], suggesting a primary pathogenic mechanism for increased IL-1 levels. In addition, chondrocytes from osteoarthritic joints are more sensitive to IL-1 than non-arthritic chondrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/78\">",
"     78",
"    </a>",
"    ]. In one study, for example, the normal cartilage produced catabolic enzymes at a four percent IL-1 receptor occupancy rate, whereas the osteoarthritic cartilage did so at only a 1 percent receptor occupancy rate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/78\">",
"     78",
"    </a>",
"    ]. Heritable differences in basal and stimulated production of IL-1 and IL-10 may also play a role in some families with a predisposition for OA [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumor necrosis factor-alpha (TNFa) may also have a role in osteoarthritis. TNFa is a cytokine with similar but less potent effects as IL-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/80,81\">",
"     80,81",
"    </a>",
"    ], and plays a role in cartilage damage in rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/80\">",
"     80",
"    </a>",
"    ]. Competitive inhibition of TNF with anti-TNF antibodies has been found to improve symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/82\">",
"     82",
"    </a>",
"    ]. By comparison, the role of TNFa in osteoarthritis is less clear, but studies suggest similar actions. In vitro studies, for example, have demonstrated that synovium from osteoarthritic knees produce TNFa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/77\">",
"     77",
"    </a>",
"    ]. In addition, one study using a canine model found increased levels of TNFa in the knees of dogs with surgically transected anterior cruciate ligaments versus the control knee [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/83\">",
"     83",
"    </a>",
"    ]. These studies therefore have only demonstrated correlation and not causation between TNFa and osteoarthritic knees.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Anabolic cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin-like growth factor (IGF-I) is an anabolic cytokine found in decreased levels in the serum of patients with osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/84\">",
"     84",
"    </a>",
"    ]. Studies have demonstrated that this cytokine increases cartilage synthesis in pig models [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/85-87\">",
"     85-87",
"    </a>",
"    ], stimulates synthesis of matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/87,88\">",
"     87,88",
"    </a>",
"    ], and promotes synthesis of prostaglandins. In addition, IGF-I levels were found to correlate with osteophyte formation, thereby suggesting that this compound may play a role in bone alterations seen in osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alteration in the relative concentrations in the synovium of IGF-I and IGF binding proteins may be important in the pathophysiology of disordered articular metabolism. In normal synovial fluid, there is a balance of circulating insulin growth factors, insulin growth factor-binding proteins, and proteases to modulate the bioactivity of insulin growth factors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/90\">",
"     90",
"    </a>",
"    ]. In osteoarthritis, however, an increased synovial concentration of IGF-I is accompanied by an increase in insulin growth factor binding protein levels in synovial fluid.",
"   </p>",
"   <p>",
"    One study evaluated the concentration of free IGF-I in human normal and osteoarthritic synovial fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/91\">",
"     91",
"    </a>",
"    ]. The levels of IGF-I in osteoarthritic synovial fluid were found to be twice as high as those in the synovial fluid of normal joints, and high concentrations of IGF-I were reported in osteoarthritic cartilage. In addition, levels of IGF-I found in normal human cartilage were more than an order of magnitude lower than those that stimulate proteoglycan synthesis in human cartilage, while IGF-I levels in osteoarthritic cartilage were in the range in which stimulation occurs.",
"   </p>",
"   <p>",
"    Transforming growth factor-beta (TGF-beta) is another cytokine implicated in maintaining cartilage via anabolic mechanisms. This compound is found in low levels in the synovium of osteoarthritic joints [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/92\">",
"     92",
"    </a>",
"    ]. The compound has been found to stimulate matrix synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/93\">",
"     93",
"    </a>",
"    ] and increase proteoglycan synthesis. TGF-beta inhibits collagen degradation by preventing collagenase release, stimulating production of TIMPs and collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/94,95\">",
"     94,95",
"    </a>",
"    ], and down regulating IL-1 receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another anabolic cytokine, osteopontin, a protein ordinarily produced by hypertrophic chondrocytes within the growth plate of bones, is also synthesized in increased amounts by human chondrocytes found in osteoarthritic articular cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. Exposure of cultured chondrocytes to osteopontin decreases the production of prostaglandin-E2 and nitric oxide in response to IL-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cytokines with both catabolic and anabolic properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin-6 has also been implicated in the development of osteoarthritis since it has been found in increased levels in arthritic joints. One study found increased levels in arthritic canine joints versus the nonarthritic control joint [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/83\">",
"     83",
"    </a>",
"    ]. IL-6 has also been found to play a role in decreased prostaglandin synthesis seen with IL-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/99\">",
"     99",
"    </a>",
"    ], and is capable of increasing TNF receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/100\">",
"     100",
"    </a>",
"    ]. However, IL-6 is also known to induce the production of tissue inhibitor of metalloproteinases-1 (TIMP-1), which may act to limit cartilage damage through negative feedback [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Thus, the role of IL-6 in osteoarthritis is complex. Given the dual role of this cytokine, it has been hypothesized that IL-6 acts as a regulatory cytokine modulating cartilage remodeling and degradation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of cytokines in osteoarthritis is complex. While some cytokines such as IL-1 are predominantly catabolic, others are predominantly anabolic such as IGF-I. Other cytokines have dual roles such as those of IL-6. It is likely that these cytokines have other as yet undetermined functions, further complicating their role in cartilage degradation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     NITRIC OXIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide, a highly reactive gas also known as endothelium derived relaxing factor, has been implicated as a pathogenic mediator in OA. As an example, nitric oxide activates metalloproteinases in articular cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/103\">",
"     103",
"    </a>",
"    ]. In addition, in a canine model of OA, the inhibition of inducible nitric oxide synthase lessened cartilage deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/104,105\">",
"     104,105",
"    </a>",
"    ]. In humans, indirect evidence that nitric oxide has a role in OA is suggested by the finding of higher levels of nitric oxide in diseased versus non-degenerated cartilage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     CALCIUM CRYSTALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium-containing pyrophosphate crystals coexist with cartilage damage in some patients with osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/107\">",
"     107",
"    </a>",
"    ]. However, it is unclear if crystals cause cartilage damage or are a result of cartilage damage, or both. Basic calcium phosphate crystals are potent inducers of COX-2 mRNA and prostaglandin E2 production by cultured fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite uncertainty about the nature of the relationship between calcium containing crystals and osteoarthritis, there appears to be a correlation between the radiographic severity of disease and the prevalence of such crystals in synovial fluid. This was illustrated when patients scheduled for total joint arthroplasty of the knee had preoperative joint fluid analysis for calcium pyrophosphate dihydrate and basic calcium phosphate crystals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/109\">",
"     109",
"    </a>",
"    ]. Among these patients, 60 percent had crystals of either or both types present. In those with radiographic scores of 2, 3, and 4, basic calcium phosphate crystals were present in 5, 7, and 20 percent, respectively.",
"   </p>",
"   <p>",
"    The presence of chondrocalcinosis on plain radiographs of the knee is not correlated with a significantly greater rate of cartilage loss. This was illustrated in an analysis of two longitudinal studies of older people that included a total of 495 participants who had baseline knee radiographs and whose knee cartilage was assessed with serial magnetic resonance imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/110\">",
"     110",
"    </a>",
"    ]. The two cohorts differed significantly in age and results were analyzed separately. In the younger cohort (265 participants, mean age 67 years) there was a significantly lower risk of progressive knee cartilage damage between MRI studies (15 months interval) in those with chondrocalcinosis (adjusted risk ratio [RR] 0.4, 95% CI 0.2-0.7), while in the older cohort (230 participants, mean age 74 years) there was no significant difference in risk of progression during three years of follow up (RR 0.9, 95% CI 0.6-1.5).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Causes of calcium crystal deposition in osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium pyrophosphate dihydrate (CPPD) crystal formation in cartilage in osteoarthritis may result from changes in the cartilage matrix that promote crystal formation or elevated levels of either calcium or inorganic pyrophosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/1\">",
"     1",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Synovial fluid levels of inorganic pyrophosphate are greater than plasma levels and correlate with radiographic joint degeneration [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Articular cartilage vesicles contain nucleoside triphosphate pyrophosphohydrolase enzyme activity, which generates inorganic pyrophosphate from ATP [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/1\">",
"       1",
"      </a>",
"      ]. In the presence of exogenous ATP, porcine articular cartilage vesicle digests from CPPD crystals [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/112,113\">",
"       112,113",
"      </a>",
"      ]; in vitro studies have shown that human osteoarthritic cartilage vesicle digests from either apatite or CPPD crystals in the presence of ATP [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TGF-beta, which has been shown to suppress urate crystal-induced inflammation, increases pyrophosphate elaboration by chondrocytes in culture [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/115\">",
"       115",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CPPD may be released by progressive cartilage fissuring that exposes and permits the escape of previously concealed crystal deposits into the joint. Crystals may then be phagocytosed by synovial cells and metabolized [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/116\">",
"       116",
"      </a>",
"      ]. Dissolution of crystals may also occur in the extracellular space by enzymatic degradation by alkaline phosphatase [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/117\">",
"       117",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Mechanisms of damage in osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most evidence in favor of a pathologic role for calcium-containing crystals in osteoarthritis has been circumstantial [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/116\">",
"     116",
"    </a>",
"    ]. As an example, one study noted that the addition of CPPD crystals to a rabbit meniscectomy model osteoarthritis resulted in more severe osteoarthritis when compared to meniscectomy without CPPD crystals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/118\">",
"     118",
"    </a>",
"    ]. CPPD crystals injected into normal joints did",
"    <strong>",
"     not",
"    </strong>",
"    cause cartilage damage.",
"   </p>",
"   <p>",
"    Calcium-containing crystals may promote articular cartilage damage by causing synovial proliferation, or by inducing the secretion of metalloproteinases or local inflammatory mediators [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Synovial proliferation is common in crystal-associated arthritis and in osteoarthritis associated with CPPD crystals [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/119-121\">",
"       119-121",
"      </a>",
"      ]. The crystals appear to be at least partially responsible for synovial proliferation as they induce mitogenesis in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/1,122\">",
"       1,122",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In turn, a synovitis is associated with the enhanced release of cytokines and metalloproteinases which promotes chondrolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/1,123\">",
"       1,123",
"      </a>",
"      ]. A role for CPPD crystals in causing the release of metalloproteinases is suggested via the inhibition of such proteinases by phosphocitrate, an agent which decreases crystalline effects and deposition [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/115,124\">",
"       115,124",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both basic calcium phosphate (BCP) (hydroxyapatite, octacalcium phosphate, tricalcium phosphate) and CPPD crystals promote the release of local mediators of inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/125\">",
"       125",
"      </a>",
"      ]. The neutrophil response to crystal-induced inflammation causes the release of leukotrienes, lysosomal proteases and chemotactic factors, which promote local injury [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/125\">",
"       125",
"      </a>",
"      ]. Specifically, CPPD crystals stimulate the in vitro production of interleukin-8 but inhibit the production of macrophage inflammatory protein-1-alpha [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/126\">",
"       126",
"      </a>",
"      ]. These differential effects may explain the predominance of polymorphonuclear neutrophils over mononuclear cells in synovial fluid seen in the presence of these crystals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Articular damage and inflammation with CPPD crystals may also be dependent upon other factors, including the quantity and form of crystals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased quantities and larger and more monoclinic crystal forms have been observed during acute inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/127\">",
"       127",
"      </a>",
"      ]. In a comparison of the effects of different BCP crystals in the rat air pouch model of inflammation, one study noted that crystals with larger surface areas and lower Ca:P ratios tended to be more inflammatory [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/128\">",
"       128",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study noted a preponderance of synovial proliferation with adherent CPPD crystals in the suprapatellar pouch of osteoarthritic knees [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/121\">",
"       121",
"      </a>",
"      ]. This finding was associated with greater articular cartilage damage of the adjacent patellofemoral articular cartilage rather than articular cartilage in the tibiofemoral compartments.",
"     </li>",
"     <li>",
"      The presence of magnesium whitlockite crystals could alter tissue compliance and cause disruption of articular surface integrity, thereby resulting in osteoarthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/1\">",
"       1",
"      </a>",
"      ]. Such crystals have been noted by transmission electron microscopy and x-ray microanalysis in normal and osteoarthritic articular cartilage [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/129\">",
"       129",
"      </a>",
"      ]. The density of crystals correlates with the degree of mechanical stress exerted on the involved joint [",
"      <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/129\">",
"       129",
"      </a>",
"      ], but these BCP crystals are not associated with structural disruption of collagen fibril orientation or chondrocyte degeneration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Calcium-containing crystals may also have direct effects on chondrocyte integrity and function. One study using porcine knee cartilage digests found that BCP crystals could contribute to abnormal chondrocyte proliferation and stimulation of chondrocyte-derived collagenase&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Familial CPPD and osteoarthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial CPPD has been associated with early onset of disease and progression to severe degenerative osteoarthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=see_link\">",
"     \"Risk factors for and possible causes of osteoarthritis\"",
"    </a>",
"    .) The identification of genetic defects in families with inherited predispositions to osteoarthritis and CPPD may lead to a better understanding of the role of CPPD in the development of osteoarthritis-related cartilage damage. As an example, the early development of osteoarthritis, spondyloepiphyseal dysplasia, and CPPD have been linked to a point mutation in a type II procollagen gene [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/131\">",
"     131",
"    </a>",
"    ]. Despite this association, multiple interacting factors, and not a single genetic defect, are most likely required for the eventual development of osteoarthritis in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SEX HORMONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gender related hormones have been considered to be possible factors in the development of osteoarthritis, particularly in women [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/132-135\">",
"     132-135",
"    </a>",
"    ]. Several epidemiologic observations indirectly support this relationship, including a female excess in prevalence and incidence of osteoarthritis beginning in the perimenopausal period, and the association between prevalent osteoarthritis and markers of endogenous sex hormone exposure, such as bone mass and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/136\">",
"     136",
"    </a>",
"    ], as well as directly measured serum estradiol&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/137\">",
"     137",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=see_link\">",
"     \"Risk factors for and possible causes of osteoarthritis\"",
"    </a>",
"    .) However, these associations do not prove causality.",
"   </p>",
"   <p>",
"    An abundance of evidence suggests that exposure to endogenous estrogen predisposes women to generalized osteoarthritis. However, studies assessing serum sex hormone levels in women with osteoarthritis and the effect of estrogen replacement therapy on the disorder are inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/134,136,138\">",
"     134,136,138",
"    </a>",
"    ]. This variation may arise because the effect of sex hormone exposure may vary with menopausal status and other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     AGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between aging and osteoarthritis is very strong. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=see_link&amp;anchor=H3#H3\">",
"     \"Risk factors for and possible causes of osteoarthritis\", section on 'Age'",
"    </a>",
"    .) But the mechanism underlying this association is uncertain. A possible link may be an age-related decrease in the number of chondrocytes in the articular cartilage. This relationship was noted in an observational study of articular cartilage obtained postmortem from 41 previously healthy organ donors or patients who suffered hip fractures requiring total hip arthroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?18/42/19114/abstract/139\">",
"     139",
"    </a>",
"    ]. The number of chondrocytes in the femoral head, when measured per gram of tissue (when released by matrix digestion) or per square mm on histologic sections, declined by approximately 50 percent from age 20 to 40 compared with age 65 or greater. In contrast, specimens of articular cartilage obtained at surgery for hip replacement for osteoarthritis from 30 patients had similar chondrocyte numbers regardless of patient age. The synthetic capacity of the chondrocytes when cultured ex-vivo did not appear to be adversely affected by aging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=see_link\">",
"       \"Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=see_link\">",
"       \"Patient information: Osteoarthritis treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38551526\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoarthritis (OA) results from articular cartilage failure induced by a complex interplay of genetic, metabolic, biochemical, and biomechanical factors with secondary components of inflammation. The process involves interactive degradation and repair processes of cartilage, bone, and synovium. The initiation of the osteoarthritic process appears to involve abnormalities in biomechanical forces",
"      <span class=\"nowrap\">",
"       and/or,",
"      </span>",
"      less often, in cartilage. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a genetic contribution to the risk of developing OA, which is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=see_link&amp;anchor=H24#H24\">",
"       \"Risk factors for and possible causes of osteoarthritis\", section on 'Genetic factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Whether the direct effect of exercise or mechanical loading is beneficial or detrimental to the health of weight-bearing cartilage likely relates to the magnitude and duration of the physical stimulus that is sensed by the chondrocytes within that cartilage. These applied external stresses are modified by several factors, including the integrity of the extracellular matrix, the strength and reflex activation of supporting muscle groups, the proprioceptive system of the involved extremity, the relative stiffness of the subchondral bone, and the presence of any abnormalities of alignment or structure. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Exercise and mechanical loading'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Effect on chondrocytes and matrix'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Effect on cartilage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Exercise and muscle weakness'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Exercise and proprioceptive defects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Mechanical loads and internal derangements'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three main groups of metalloproteases, a class of zinc-containing enzymes and key elements in the degradation of cartilage and development of OA. These include collagenase, stromelysin, and gelatinase. These enzymes are inhibited by tissue inhibitors of metalloproteases (TIMPs). When the ratio of these two groups of balancing proteins is altered, the catabolic metalloproteases become active and enhance cartilage destruction. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Proteases'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Collagenase'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Stromelysin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Gelatinase'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Other proteases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of cytokines in OA is complex. While some cytokines such as IL-1 are predominantly catabolic, others are predominantly anabolic such as IGF-I. Other cytokines have dual roles such as those of IL-6. It is likely that these cytokines have other as yet undetermined functions, further complicating their role in cartilage degradation. Nitric oxide, a highly reactive gas also known as endothelium derived relaxing factor, has also been implicated as a pathogenic mediator in OA. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Cytokines'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Catabolic cytokines'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Anabolic cytokines'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Cytokines with both catabolic and anabolic properties'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Nitric oxide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Calcium-containing pyrophosphate crystals coexist with cartilage damage in some patients with OA, but it is unclear if crystals cause",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      result from cartilage damage. Basic calcium phosphate crystals are potent inducers of COX-2 mRNA and prostaglandin E2 production by cultured fibroblasts. There appears to be a correlation between the radiographic severity of disease and the prevalence of calcium-containing crystals in synovial fluid. However, the presence of chondrocalcinosis on plain radiographs of the knee is not correlated with a significantly greater rate of cartilage loss. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Calcium crystals'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Causes of calcium crystal deposition in osteoarthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Mechanisms of damage in osteoarthritis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Familial CPPD and osteoarthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gender related hormones are possible factors in the development of OA, particularly in women, and exposure to endogenous estrogen predisposes women to generalized OA. However, studies assessing serum sex hormone levels in women with OA and the effect of estrogen replacement therapy on the disorder are inconclusive. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Sex hormones'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The association between aging and OA is very strong, but the mechanism underlying this association is uncertain. A possible link may be an age-related decrease in the number of chondrocytes in the articular cartilage. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Aging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/1\">",
"      Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971; 53:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/2\">",
"      Hulth A, Lindberg L, Telhag H. Mitosis in human osteoarthritic cartilage. Clin Orthop Relat Res 1972; 84:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/3\">",
"      Ryu J, Treadwell BV, Mankin HJ. Biochemical and metabolic abnormalities in normal and osteoarthritic human articular cartilage. Arthritis Rheum 1984; 27:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/4\">",
"      Lippiello L, Hall D, Mankin HJ. Collagen synthesis in normal and osteoarthritic human cartilage. J Clin Invest 1977; 59:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/5\">",
"      Brandt KD. Enhanced extractability of articular cartilage protoglycans in osteoarthrosis. Biochem J 1974; 143:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/6\">",
"      Altman RD, Pita JC, Howell DS. Degradation of proteoglycans in human osteoarthritic cartilage. Arthritis Rheum 1973; 16:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/7\">",
"      Jasin HE. Immune mechanisms in osteoarthritis. Semin Arthritis Rheum 1989; 18:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/8\">",
"      S&ouml;der O, Madsen K. Stimulation of chondrocyte DNA synthesis by interleukin-1. Br J Rheumatol 1988; 27:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/9\">",
"      Ikebe T, Hirata M, Koga T. Effects of human recombinant tumor necrosis factor-alpha and interleukin 1 on the synthesis of glycosaminoglycan and DNA in cultured rat costal chondrocytes. J Immunol 1988; 140:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/10\">",
"      Jasin HE, Dingle JT. Human mononuclear cell factors mediate cartilage matrix degradation through chondrocyte activation. J Clin Invest 1981; 68:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/11\">",
"      Deshmukh-Phadke K, Lawrence M, Nanda S. Synthesis of collagenase and neutral proteases by articular chondrocytes: stimulation by a macrophage-derived factor. Biochem Biophys Res Commun 1978; 85:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/12\">",
"      Rosen DM, Stempien SA, Thompson AY, Seyedin SM. Transforming growth factor-beta modulates the expression of osteoblast and chondroblast phenotypes in vitro. J Cell Physiol 1988; 134:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/13\">",
"      O'Keefe RJ, Puzas JE, Brand JS, Rosier RN. Effects of transforming growth factor-beta on matrix synthesis by chick growth plate chondrocytes. Endocrinology 1988; 122:2953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/14\">",
"      Heineg&aring;rd D, Inerot S, Wieslander J, Lindblad G. A method for the quantification of cartilage proteoglycan structures liberated to the synovial fluid during developing degenerative joint disease. Scand J Clin Lab Invest 1985; 45:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/15\">",
"      Witter J, Roughley PJ, Webber C, et al. The immunologic detection and characterization of cartilage proteoglycan degradation products in synovial fluids of patients with arthritis. Arthritis Rheum 1987; 30:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/16\">",
"      Cheung HS, Ryan LM, Kozin F, McCarty DJ. Identification of collagen subtypes in synovial fluid sediments from arthritic patients. Am J Med 1980; 68:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/17\">",
"      Kitridou R, McCarty DJ, Prockop DJ, Hummeler K. Identification of collagen in synovial fluid. Arthritis Rheum 1969; 12:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/18\">",
"      Fisher WD, Golds EE, van der Rest M, et al. Stimulation of collagenase secretion from rheumatoid synovial tissue by human collagen peptides. J Bone Joint Surg Am 1982; 64:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/19\">",
"      Hanauske-Abel HM, Pontz BF, Schorlemmer HU. Cartilage specific collagen activates macrophages and the alternative pathway of complement: evidence for an immunopathogenic concept of rheumatoid arthritis. Ann Rheum Dis 1982; 41:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/20\">",
"      Goto M, Yoshinoya S, Miyamoto T, et al. Stimulation of interleukin-1 alpha and interleukin-1 beta release from human monocytes by cyanogen bromide peptides of type II collagen. Arthritis Rheum 1988; 31:1508.",
"     </a>",
"    </li>",
"    <li>",
"     Peyron JG, Altman RD. The epidemiology of osteoarthritis. In: Osteoarthritis: Diagnosis and Management, Second Edition, Moskowitz RW, Howell DS, Goldberg VC, Mankin HJ (Eds), WB Saunders, Phhiladelphia 1992. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/22\">",
"      Mow VC, Ratcliffe A, Poole AR. Cartilage and diarthrodial joints as paradigms for hierarchical materials and structures. Biomaterials 1992; 13:67.",
"     </a>",
"    </li>",
"    <li>",
"     Mankin HJ, Brandt KD. Biochemistry and metabolism of articular cartilage in osteoarthritis. In: Osteoarthritis: Diagnosis and Management, Second Edition, Moskowitz RW, Howell DS, Goldberg VC, Mankin HJ (Eds), WB Saunders, Philadelphia 1992. p.109.",
"    </li>",
"    <li>",
"     Byer PD, Baylis MT, Maroudas A, et al. Hypothesizing about joints. In: Studies in Joint Diseases 2, Maroudas A, Holborow EJ (Eds), Pitman, London 1983. p.241.",
"    </li>",
"    <li>",
"     Jimenez SA, Ala-Kokko L, Ahmad N, et al. Type II collage gene mutations in familial osteoarthritis. In: Articular Cartilage and osteoarthritis (workshop), Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC (Eds), Raven Press, New York 1992. p.167.",
"    </li>",
"    <li>",
"     Pelletier JP, Martel-Pelletier J, Howell DS. Etiopathogenesis of osteoarthritis. In: Arthritis and Allied Conditions: A Textbook of Rheumatology, 13th Edition, Koopman WJ (Ed), Williams and Wilkins, Baltimore 1997. p.1969.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/27\">",
"      Felson DT, Chaisson CE, Hill CL, et al. The association of bone marrow lesions with pain in knee osteoarthritis. Ann Intern Med 2001; 134:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/28\">",
"      Lo GH, Hunter DJ, Zhang Y, et al. Bone marrow lesions in the knee are associated with increased local bone density. Arthritis Rheum 2005; 52:2814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/29\">",
"      Urban JP. The chondrocyte: a cell under pressure. Br J Rheumatol 1994; 33:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/30\">",
"      Radin EL, Yang KH, Riegger C, et al. Relationship between lower limb dynamics and knee joint pain. J Orthop Res 1991; 9:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/31\">",
"      Brandt KD. Putting some muscle into osteoarthritis. Ann Intern Med 1997; 127:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/32\">",
"      Lahr DD. Does running exercise cause osteoarthritis? Md Med J 1996; 45:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/33\">",
"      Lane NE. Exercise: a cause of osteoarthritis. J Rheumatol Suppl 1995; 43:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/34\">",
"      Sah RL, Kim YJ, Doong JY, et al. Biosynthetic response of cartilage explants to dynamic compression. J Orthop Res 1989; 7:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/35\">",
"      Korver TH, van de Stadt RJ, Kiljan E, et al. Effects of loading on the synthesis of proteoglycans in different layers of anatomically intact articular cartilage in vitro. J Rheumatol 1992; 19:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/36\">",
"      Reneman RS, Arts T, van Bilsen M, et al. Mechanoperception and mechanotransduction in cardiac adaptation: mechanical and molecular aspects. Adv Exp Med Biol 1995; 382:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/37\">",
"      Davies PF. Flow-mediated endothelial mechanotransduction. Physiol Rev 1995; 75:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/38\">",
"      Millward-Sadler SJ, Wright MO, Davies LW, et al. Mechanotransduction via integrins and interleukin-4 results in altered aggrecan and matrix metalloproteinase 3 gene expression in normal, but not osteoarthritic, human articular chondrocytes. Arthritis Rheum 2000; 43:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/39\">",
"      Nerlich AG, Schleicher ED, Boos N. 1997 Volvo Award winner in basic science studies. Immunohistologic markers for age-related changes of human lumbar intervertebral discs. Spine (Phila Pa 1976) 1997; 22:2781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/40\">",
"      Mizrahi J, Maroudas A, Lanir Y, et al. The \"instantaneous\" deformation of cartilage: effects of collagen fiber orientation and osmotic stress. Biorheology 1986; 23:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/41\">",
"      Buckwalter JA. Osteoarthritis and articular cartilage use, disuse, and abuse: experimental studies. J Rheumatol Suppl 1995; 43:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/42\">",
"      Panush RS, Brown DG. Exercise and arthritis. Sports Med 1987; 4:54.",
"     </a>",
"    </li>",
"    <li>",
"     Helminen HJ, Kiviranta I, Saamanen AM, et al. Effect of motion and load on articular cartilage in animal models. In: Articular Cartilage and Osteoarthritis, Kuettner KE, Schleyerbach R, Peyron JG, Hascall VC (Eds), Raven Press, New York 1992. p.501.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/44\">",
"      Kiviranta I, Tammi M, Jurvelin J, et al. Articular cartilage thickness and glycosaminoglycan distribution in the canine knee joint after strenuous running exercise. Clin Orthop Relat Res 1992; :302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/45\">",
"      Arokoski J, Kiviranta I, Jurvelin J, et al. Long-distance running causes site-dependent decrease of cartilage glycosaminoglycan content in the knee joints of beagle dogs. Arthritis Rheum 1993; 36:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/46\">",
"      Grumbles RM, Howell DS, Howard GA, et al. Cartilage metalloproteases in disuse atrophy. J Rheumatol Suppl 1995; 43:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/47\">",
"      Palmoski MJ, Colyer RA, Brandt KD. Joint motion in the absence of normal loading does not maintain normal articular cartilage. Arthritis Rheum 1980; 23:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/48\">",
"      Vincent TL, Hermansson MA, Hansen UN, et al. Basic fibroblast growth factor mediates transduction of mechanical signals when articular cartilage is loaded. Arthritis Rheum 2004; 50:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/49\">",
"      Fisher NM, Kame VD Jr, Rouse L, Pendergast DR. Quantitative evaluation of a home exercise program on muscle and functional capacity of patients with osteoarthritis. Am J Phys Med Rehabil 1994; 73:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/50\">",
"      Slemenda C, Brandt KD, Heilman DK, et al. Quadriceps weakness and osteoarthritis of the knee. Ann Intern Med 1997; 127:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/51\">",
"      Jefferson RJ, Collins JJ, Whittle MW, et al. The role of the quadriceps in controlling impulsive forces around heel strike. Proc Inst Mech Eng H 1990; 204:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/52\">",
"      Sharma L, Pai YC. Impaired proprioception and osteoarthritis. Curr Opin Rheumatol 1997; 9:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/53\">",
"      HILL AV. Production and absorption of work by muscle. Science 1960; 131:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/54\">",
"      Hurley MV, Newham DJ. The influence of arthrogenous muscle inhibition on quadriceps rehabilitation of patients with early, unilateral osteoarthritic knees. Br J Rheumatol 1993; 32:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/55\">",
"      Moskowitz RW, Davis W, Sammarco J, et al. Experimentally induced degenerative joint lesions following partial meniscectomy in the rabbit. Arthritis Rheum 1973; 16:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/56\">",
"      Muir H. Heberden Oration, 1976. Molecular approach to the understanding of osteoarthrosis. Ann Rheum Dis 1977; 36:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/57\">",
"      Vilensky JA, O'Connor BL, Brandt KD, et al. Serial kinematic analysis of the canine hindlimb joints after deafferentation and anterior cruciate ligament transection. Osteoarthritis Cartilage 1997; 5:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/58\">",
"      Miller EJ, Harris ED Jr, Chung E, et al. Cleavage of Type II and III collagens with mammalian collagenase: site of cleavage and primary structure at the NH2-terminal portion of the smaller fragment released from both collagens. Biochemistry 1976; 15:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/59\">",
"      Vincenti MP, Clark IM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum 1994; 37:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/60\">",
"      Shlopov BV, Lie WR, Mainardi CL, et al. Osteoarthritic lesions: involvement of three different collagenases. Arthritis Rheum 1997; 40:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/61\">",
"      Ollivierre F, Gubler U, Towle CA, et al. Expression of IL-1 genes in human and bovine chondrocytes: a mechanism for autocrine control of cartilage matrix degradation. Biochem Biophys Res Commun 1986; 141:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/62\">",
"      Morris EA, Treadwell BV. Effect of interleukin 1 on articular cartilage from young and aged horses and comparison with metabolism of osteoarthritic cartilage. Am J Vet Res 1994; 55:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/63\">",
"      Murphy G, Cockett MI, Stephens PE, et al. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J 1987; 248:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/64\">",
"      Okada Y, Konomi H, Yada T, et al. Degradation of type IX collagen by matrix metalloproteinase 3 (stromelysin) from human rheumatoid synovial cells. FEBS Lett 1989; 244:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/65\">",
"      Mohtai M, Smith RL, Schurman DJ, et al. Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest 1993; 92:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/66\">",
"      Tetlow LC, Adlam DJ, Woolley DE. Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum 2001; 44:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/67\">",
"      Dean DD, Martel-Pelletier J, Pelletier JP, et al. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 1989; 84:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/68\">",
"      Campbell IK, Piccoli DS, Butler DM, et al. Recombinant human interleukin-1 stimulates human articular cartilage to undergo resorption and human chondrocytes to produce both tissue- and urokinase-type plasminogen activator. Biochim Biophys Acta 1988; 967:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/69\">",
"      Martel-Pelletier J, Faure MP, McCollum R, et al. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage. J Rheumatol 1991; 18:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/70\">",
"      B&ouml;hm BB, Aigner T, Gehrsitz A, et al. Up-regulation of MDC15 (metargidin) messenger RNA in human osteoarthritic cartilage. Arthritis Rheum 1999; 42:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/71\">",
"      Eastgate JA, Symons JA, Wood NC, et al. Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis. Lancet 1988; 2:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/72\">",
"      Kandel RA, Dinarello CA, Biswas C. The stimulation of collagenase production in rabbit articular chondrocytes by interleukin-1 is increased by collagens. Biochem Int 1987; 15:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/73\">",
"      Pettipher ER, Higgs GA, Henderson B. Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci U S A 1986; 83:8749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/74\">",
"      Dodge GR, Poole AR. Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. J Clin Invest 1989; 83:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/75\">",
"      Westacott CI, Sharif M. Cytokines in osteoarthritis: mediators or markers of joint destruction? Semin Arthritis Rheum 1996; 25:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/76\">",
"      Agarwal S, Deschner J, Long P, et al. Role of NF-kappaB transcription factors in antiinflammatory and proinflammatory actions of mechanical signals. Arthritis Rheum 2004; 50:3541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/77\">",
"      Smith MD, Triantafillou S, Parker A, et al. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997; 24:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/78\">",
"      Warnock MG, Sharif M, Elson CJ. IL-1-beta at physiological concentration stimulates degradation of human articular cartilage. Bone Miner 1994; 25(Suppl):S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/79\">",
"      Riyazi N, Slagboom E, de Craen AJ, et al. Association of the risk of osteoarthritis with high innate production of interleukin-1beta and low innate production of interleukin-10 ex vivo, upon lipopolysaccharide stimulation. Arthritis Rheum 2005; 52:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/80\">",
"      Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/81\">",
"      Campbell IK, Piccoli DS, Roberts MJ, et al. Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum 1990; 33:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/82\">",
"      Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/83\">",
"      Venn G, Nietfeld JJ, Duits AJ, et al. Elevated synovial fluid levels of interleukin-6 and tumor necrosis factor associated with early experimental canine osteoarthritis. Arthritis Rheum 1993; 36:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/84\">",
"      Denko CW, Boja B, Moskowitz RW. Growth promoting peptides in osteoarthritis: insulin, insulin-like growth factor-1, growth hormone. J Rheumatol 1990; 17:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/85\">",
"      Tyler JA. Insulin-like growth factor 1 can decrease degradation and promote synthesis of proteoglycan in cartilage exposed to cytokines. Biochem J 1989; 260:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/86\">",
"      Osborn KD, Trippel SB, Mankin HJ. Growth factor stimulation of adult articular cartilage. J Orthop Res 1989; 7:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/87\">",
"      McQuillan DJ, Handley CJ, Robinson HC. Control of proteoglycan biosynthesis. Further studies on the effect of serum on cultured bovine articular cartilage. Biochem J 1986; 237:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/88\">",
"      McQuillan DJ, Handley CJ, Campbell MA, et al. Stimulation of proteoglycan biosynthesis by serum and insulin-like growth factor-I in cultured bovine articular cartilage. Biochem J 1986; 240:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/89\">",
"      Schouten JS, Van den Ouweland FA, Valkenburg HA, Lamberts SW. Insulin-like growth factor-1: a prognostic factor of knee osteoarthritis. Br J Rheumatol 1993; 32:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/90\">",
"      Matsumoto T, Gargosky SE, Iwasaki K, Rosenfeld RG. Identification and characterization of insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP proteases in human synovial fluid. J Clin Endocrinol Metab 1996; 81:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/91\">",
"      Schneiderman R, Rosenberg N, Hiss J, et al. Concentration and size distribution of insulin-like growth factor-I in human normal and osteoarthritic synovial fluid and cartilage. Arch Biochem Biophys 1995; 324:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/92\">",
"      Fava R, Olsen N, Keski-Oja J, et al. Active and latent forms of transforming growth factor beta activity in synovial effusions. J Exp Med 1989; 169:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/93\">",
"      Wahl SM, McCartney-Francis N, Mergenhagen SE. Inflammatory and immunomodulatory roles of TGF-beta. Immunol Today 1989; 10:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/94\">",
"      Luyten FP, Hascall VC, Nissley SP, et al. Insulin-like growth factors maintain steady-state metabolism of proteoglycans in bovine articular cartilage explants. Arch Biochem Biophys 1988; 267:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/95\">",
"      Morales TI, Roberts AB. Transforming growth factor beta regulates the metabolism of proteoglycans in bovine cartilage organ cultures. J Biol Chem 1988; 263:12828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/96\">",
"      Dubois CM, Ruscetti FW, Palaszynski EW, et al. Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action. J Exp Med 1990; 172:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/97\">",
"      Pullig O, Weseloh G, Gauer S, Swoboda B. Osteopontin is expressed by adult human osteoarthritic chondrocytes: protein and mRNA analysis of normal and osteoarthritic cartilage. Matrix Biol 2000; 19:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/98\">",
"      Attur MG, Dave MN, Stuchin S, et al. Osteopontin: an intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum 2001; 44:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/99\">",
"      Nietfeld JJ, Wilbrink B, Helle M, et al. Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum 1990; 33:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/100\">",
"      Van Bladel S, Libert C, Fiers W. Interleukin-6 enhances the expression of tumor necrosis factor receptors on hepatoma cells and hepatocytes. Cytokine 1991; 3:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/101\">",
"      Lotz M, Guerne PA. Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA). J Biol Chem 1991; 266:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/102\">",
"      Sato T, Ito A, Mori Y. Interleukin 6 enhances the production of tissue inhibitor of metalloproteinases (TIMP) but not that of matrix metalloproteinases by human fibroblasts. Biochem Biophys Res Commun 1990; 170:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/103\">",
"      Murrell GA, Jang D, Williams RJ. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995; 206:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/104\">",
"      Pelletier JP, Lascau-Coman V, Jovanovic D, et al. Selective inhibition of inducible nitric oxide synthase in experimental osteoarthritis is associated with reduction in tissue levels of catabolic factors. J Rheumatol 1999; 26:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/105\">",
"      Pelletier JP, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum 2000; 43:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/106\">",
"      Salvatierra J, Escames G, Hernandez P, et al. Cartilage and serum levels of nitric oxide in patients with hip osteoarthritis. J Rheumatol 1999; 26:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/107\">",
"      Schumacher HR Jr. Synovial inflammation, crystals, and osteoarthritis. J Rheumatol Suppl 1995; 43:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/108\">",
"      Morgan MP, Whelan LC, Sallis JD, et al. Basic calcium phosphate crystal-induced prostaglandin E2 production in human fibroblasts: role of cyclooxygenase 1, cyclooxygenase 2, and interleukin-1beta. Arthritis Rheum 2004; 50:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/109\">",
"      Derfus BA, Kurian JB, Butler JJ, et al. The high prevalence of pathologic calcium crystals in pre-operative knees. J Rheumatol 2002; 29:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/110\">",
"      Neogi T, Nevitt M, Niu J, et al. Lack of association between chondrocalcinosis and increased risk of cartilage loss in knees with osteoarthritis: results of two prospective longitudinal magnetic resonance imaging studies. Arthritis Rheum 2006; 54:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/111\">",
"      Silcox DC, McCarty DJ Jr. Elevated inorganic pyrophosphate concentrations in synovial fluids in osteoarthritis and pseudogout. J Lab Clin Med 1974; 83:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/112\">",
"      Derfus BA, Rachow JW, Mandel NS, et al. Articular cartilage vesicles generate calcium pyrophosphate dihydrate-like crystals in vitro. Arthritis Rheum 1992; 35:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/113\">",
"      Derfus B, Steinberg M, Mandel N, et al. Characterization of an additional articular cartilage vesicle fraction that generates calcium pyrophosphate dihydrate crystals in vitro. J Rheumatol 1995; 22:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/114\">",
"      Derfus B, Kranendonk S, Camacho N, et al. Human osteoarthritic cartilage matrix vesicles generate both calcium pyrophosphate dihydrate and apatite in vitro. Calcif Tissue Int 1998; 63:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/115\">",
"      Schumacher HR Jr. Crystal deposition disease. Curr Opin Rheumatol 1997; 9:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/116\">",
"      Halverson PB. Calcium crystal-associated diseases. Curr Opin Rheumatol 1996; 8:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/117\">",
"      Xu Y, Pritzker KP, Cruz TF. Characterization of chondrocyte alkaline phosphatase as a potential mediator in the dissolution of calcium pyrophosphate dihydrate crystals. J Rheumatol 1994; 21:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/118\">",
"      Fam AG, Morava-Protzner I, Purcell C, et al. Acceleration of experimental lapine osteoarthritis by calcium pyrophosphate microcrystalline synovitis. Arthritis Rheum 1995; 38:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/119\">",
"      Klashman DJ, Moreland LW, Ike RW, Kalunian KC. Occult presence of CPPD crystals in patients undergoing arthroscopic knee irrigation for refractory pain related to OA. Arthritis Rheum 1994; 37:S240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/120\">",
"      Garancis JC, Cheung HS, Halverson PB, McCarty DJ. \"Milwaukee shoulder\"--association of microspheroids containing hydroxyapatite crystals, active collagenase, ad neutral protease with rotator cuff defects. III. Morphologic and biochemical studies of an excised synovium showing chondromatosis. Arthritis Rheum 1981; 24:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/121\">",
"      Kalunian KC, Moreland LW, Klashman DJ, et al. Visually-guided irrigation in patients with early knee osteoarthritis: a multicenter randomized, controlled trial. Osteoarthritis Cartilage 2000; 8:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/122\">",
"      Cheung HS, Story MT, McCarty DJ. Mitogenic effects of hydroxyapatite and calcium pyrophosphate dihydrate crystals on cultured mammalian cells. Arthritis Rheum 1984; 27:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/123\">",
"      McCarthy GM, Mitchell PG, Struve JA, Cheung HS. Basic calcium phosphate crystals cause coordinate induction and secretion of collagenase and stromelysin. J Cell Physiol 1992; 153:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/124\">",
"      Cheung HS, Sallis JD, Struve JA. Specific inhibition of basic calcium phosphate and calcium pyrophosphate crystal-induction of metalloproteinase synthesis by phosphocitrate. Biochim Biophys Acta 1996; 1315:105.",
"     </a>",
"    </li>",
"    <li>",
"     Cheung HS, Ryan LM. Role of crystal deposition in matrix degradation. In: Joint Cartilage Degradation, Woessner JF, Howell DS (Eds), Marcel Dekker, New York 1995. p.209.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/126\">",
"      Hachicha M, Naccache PH, McColl SR. Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. J Exp Med 1995; 182:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/127\">",
"      Swan A, Heywood B, Chapman B, et al. Evidence for a causal relationship between the structure, size, and load of calcium pyrophosphate dihydrate crystals, and attacks of pseudogout. Ann Rheum Dis 1995; 54:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/128\">",
"      Prudhommeaux F, Schiltz C, Liot&eacute; F, et al. Variation in the inflammatory properties of basic calcium phosphate crystals according to crystal type. Arthritis Rheum 1996; 39:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/129\">",
"      Scotchford CA, Ali SY. Magnesium whitlockite deposition in articular cartilage: a study of 80 specimens from 70 patients. Ann Rheum Dis 1995; 54:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/130\">",
"      Mitchell PG, Struve JA, McCarthy GM, Cheung HS. Basic calcium phosphate crystals stimulate cell proliferation and collagenase message accumulation in cultured adult articular chondrocytes. Arthritis Rheum 1992; 35:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/131\">",
"      Reginato AJ, Passano GM, Neumann G, et al. Familial spondyloepiphyseal dysplasia tarda, brachydactyly, and precocious osteoarthritis associated with an arginine 75--&gt;cysteine mutation in the procollagen type II gene in a kindred of Chiloe Islanders. I. Clinical, radiographic, and pathologic findings. Arthritis Rheum 1994; 37:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/132\">",
"      Cecil RL, Archer BH. Classification and treatment of chronic arthritis. JAMA 1926; 87:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/133\">",
"      KELLGREN JH, MOORE R. Generalized osteoarthritis and Heberden's nodes. Br Med J 1952; 1:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/134\">",
"      Spector TD, Campion GD. Generalised osteoarthritis: a hormonally mediated disease. Ann Rheum Dis 1989; 48:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/135\">",
"      Rosner IA, Goldberg VM, Moskowitz RW. Estrogens and osteoarthritis. Clin Orthop Relat Res 1986; :77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/136\">",
"      Nevitt MC, Felson DT. Sex hormones and the risk of osteoarthritis in women: epidemiological evidence. Ann Rheum Dis 1996; 55:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/137\">",
"      Sowers MR, McConnell D, Jannausch M, et al. Estradiol and its metabolites and their association with knee osteoarthritis. Arthritis Rheum 2006; 54:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/138\">",
"      Nevitt MC, Felson DT, Williams EN, Grady D. The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2001; 44:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/42/19114/abstract/139\">",
"      Bobacz K, Erlacher L, Smolen J, et al. Chondrocyte number and proteoglycan synthesis in the aging and osteoarthritic human articular cartilage. Ann Rheum Dis 2004; 63:1618.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5498 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-59E8FFCE15-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19114=[""].join("\n");
var outline_f18_42_19114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38551526\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETIC PREDISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EXERCISE AND MECHANICAL LOADING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect on chondrocytes and matrix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Effect on cartilage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Exercise and muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Exercise and proprioceptive defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mechanical loads and internal derangements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROTEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Collagenase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stromelysin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gelatinase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other proteases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CYTOKINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Catabolic cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Anabolic cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cytokines with both catabolic and anabolic properties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      NITRIC OXIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      CALCIUM CRYSTALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Causes of calcium crystal deposition in osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Mechanisms of damage in osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Familial CPPD and osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SEX HORMONES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      AGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38551526\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34890?source=related_link\">",
"      Overview of running injuries of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/46/16098?source=related_link\">",
"      Patient information: Osteoarthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=related_link\">",
"      Patient information: Osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/43/29370?source=related_link\">",
"      Risk factors for and possible causes of osteoarthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_42_19115="Epidemiology of ehrlichiosis";
var content_f18_42_19115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F64475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F64475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Epidemiology of ehrlichiosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        HME",
"       </td>",
"       <td class=\"subtitle1\">",
"        HGA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etiologic agent",
"       </td>",
"       <td>",
"        E. chaffeensis",
"       </td>",
"       <td>",
"        A. phagocytophilum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percent with tick exposure",
"       </td>",
"       <td>",
"        80-90",
"       </td>",
"       <td>",
"        45-85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percent with tick bite",
"       </td>",
"       <td>",
"        68",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Vectors",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Amblyomma americanum",
"       </td>",
"       <td>",
"        Ixodes scapularis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ixodes pacificus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suspected animal reserve",
"       </td>",
"       <td>",
"        Deer",
"       </td>",
"       <td>",
"        White-footed mouse",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Median age of patient",
"       </td>",
"       <td>",
"        44",
"       </td>",
"       <td>",
"        67",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19115=[""].join("\n");
var outline_f18_42_19115=null;
var title_f18_42_19116="Proliferative bronchiolitis";
var content_f18_42_19116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63546&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders associated with the histologic finding of proliferative bronchiolitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Cryptogenic organizing pneumonitis (idiopathic BOOP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic eosinophilic pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Connective tissue diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Polymyositis/dermatomyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organ transplantation - bone marrow, heart-lung, or lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Organizing acute infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mycoplasma pneumoniae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Legionella pneumophila",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Influenza",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        HIV-infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pneumocystis carinii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Organizing diffuse alveolar damage/adult respiratory distress syndrome (ARDS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitides, especially granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Drug-induced reactions (examples)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        L-tryptophan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Busulfan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Free-base cocaine use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic thyroiditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcerative colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irradiation or aspiration pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distal to bronchial obstruction, \"obstructive pneumonitis\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic heart or renal failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Common variable immunodeficiency syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: King TE Jr. Bronchiolitis Obliterans. In: Interstitial Lung Disease, Schwartz MI, King TE Jr (Eds), Mosby-Year Book, Philadelphia, 1993, p.463.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19116=[""].join("\n");
var outline_f18_42_19116=null;
var title_f18_42_19117="Drivers with SVT";
var content_f18_42_19117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommendations for certification for commercial drivers with SVT",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Physiologic/functional",
"      </td>",
"      <td class=\"subtitle1\">",
"       Certification",
"      </td>",
"      <td class=\"subtitle1\">",
"       Re-certification",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\">",
"       Atrial fibrillation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Lone atrial fibrillation",
"      </td>",
"      <td class=\"sublist_other\">",
"       Good prognosis and low risk for stroke",
"      </td>",
"      <td class=\"sublist_other\">",
"       Yes",
"      </td>",
"      <td class=\"sublist_other\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" rowspan=\"4\">",
"       Atrial fibrillation as cause of or a risk for stroke",
"      </td>",
"      <td class=\"sublist_other\" rowspan=\"4\">",
"       Risk for stroke decreased by anticoagulation",
"      </td>",
"      <td class=\"sublist_other\">",
"       Yes if:",
"      </td>",
"      <td class=\"sublist_other\" rowspan=\"4\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Anticoagulated adequately for at least 1 month",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Anticoagulation monitored by at least monthly INR",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Rate/rhythm control deemed adequate (recommend assessment by cardiologist)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\" rowspan=\"5\">",
"       Atrial fibrillation following thoracic surgery",
"      </td>",
"      <td class=\"sublist_other\" rowspan=\"5\">",
"       Good prognosis and duration usually limited",
"      </td>",
"      <td class=\"sublist_other\">",
"       In atrial fibrillation at time of return to work",
"      </td>",
"      <td class=\"sublist_other\" rowspan=\"5\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist_other\">",
"       Yes if:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Anticoagulated adequately for at least 1 month",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Anticoagulation monitored by at least monthly INR",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Rate/rhythm control deemed adequate (recommend assessment by cardiologist)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       Atrial flutter",
"      </td>",
"      <td rowspan=\"5\">",
"       Same as for atrial fibrillation",
"      </td>",
"      <td>",
"       Same as for atrial fibrillation",
"      </td>",
"      <td>",
"       Same as for atrial fibrillation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"4\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Isthmus ablation performed and at least 1 month after procedure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Arrhythmia successfully treated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Cleared by electrophysiologist",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Multifocal atrial tachycardia",
"      </td>",
"      <td rowspan=\"6\">",
"       Often associated with comorbidities, such as lung disease, that may impair prognosis",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"4\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Asymptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Unless associated condition is disqualifying",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No, if symptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"2\">",
"       Annual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Symptoms controlled and secondary cause is not exclusionary",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       <p>",
"        Atrioventricular Nodal Reentrant Tachycardia (AVNRT)",
"       </p>",
"       <p>",
"        Atrioventricular Reentrant Tachycardia (AVRT) and Wolff-Parkinson-White (WPW) syndrome",
"       </p>",
"       <p>",
"        Atrial tachycardia",
"       </p>",
"       <p>",
"        Junctional tachycardia",
"       </p>",
"      </td>",
"      <td rowspan=\"6\">",
"       <p>",
"        Prognosis generally excellent, but may rarely have syncope or symptoms of cerebral hypoperfusion",
"       </p>",
"       <p>",
"        For those with WPW, preexcitation presents risk for death or syncope if atrial fibrillation develops",
"       </p>",
"      </td>",
"      <td class=\"sublist1_start\">",
"       No if:",
"      </td>",
"      <td rowspan=\"3\">",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Symptomatic or",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - WPW with atrial fibrillation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Yes if:",
"      </td>",
"      <td rowspan=\"3\">",
"       <p>",
"        Annual",
"       </p>",
"       <p>",
"        Recommend consultation with cardiologist",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Asymptomatic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Treated and asymptomatic for at least 1 month and assessed and cleared by expert in cardiac arrhythmias",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Blumenthal R, Braunstein J, Connolly H, et al. Cardiovascular Advisory Panel Guidelines for the Medical Examination of Commercial Motor Vehicle Drivers, October 2002. Federal Motor Carrier Safety Administration.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19117=[""].join("\n");
var outline_f18_42_19117=null;
var title_f18_42_19118="Bisphos trials MBC";
var content_f18_42_19118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pivotal phase III trials of bisphosphonates in patients with bone metastases from breast cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Bisphosphonate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comparator",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sample size",
"       </td>",
"       <td class=\"subtitle1\">",
"        Results",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Pamidronate 90 mg IV three to four times weekly for 12 months",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td rowspan=\"6\">",
"        Placebo for 12 months",
"       </td>",
"       <td rowspan=\"6\">",
"        382; patients on chemotherapy with at least one lytic lesion",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Results favored pamidronate for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Time to first SRE: 13.1 vs. 7.0 months, p = 0.005",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Proportion of patients with SRE 43 vs. 56 percent, p = 0.008",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bone pain: p = 0.046",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Performance status: p = 0.027",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Overall survival was not significantly affected by pamidronate (median survival 14.8 vs. 14.2 months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Pamidronate 90 mg IV three to four times weekly for 24 months",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td rowspan=\"6\">",
"        Placebo for 24 months",
"       </td>",
"       <td rowspan=\"6\">",
"        374; patients on endocrine therapy",
"       </td>",
"       <td>",
"        Results favored pamidronate for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Skeletal morbidity rate at 12, 18 and 24 cycles p = 0.028, 0.023, and 0.008, respectively",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Proportion of patients having SREs at 24 months: 56 vs. 67 percent at 24 cycles; p = 0.027",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Time to first SRE: 10.4 vs. 6.9 months, p = 0.049",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bone pain: p = 0.002",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Median survival was unchanged (37 months)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Pamidronate 90 mg IV three to four times weekly; up to 24 months",
"        <sup>",
"         [3]",
"        </sup>",
"        (this report is a continuation of above study",
"        <sup>",
"         [1]",
"        </sup>",
"        )",
"       </td>",
"       <td rowspan=\"4\">",
"        Placebo up to 24 months",
"       </td>",
"       <td rowspan=\"4\">",
"        382; patients on chemotherapy with at least one lytic lesion",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Results favored pamidronate for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Proportion of patients with any SREs at 15, 18, 21 &amp; 24 months; p&lt;0.001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Long-term treatment did not result in any unexpected adverse events",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Survival did not differ between the two groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Zoledronic acid 4 or 8 mg",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td rowspan=\"4\">",
"        Pamidronate 90 mg",
"       </td>",
"       <td rowspan=\"4\">",
"        287 patients HCM",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Results favored zoledronic acid for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Complete response rate by day 10; p = 0.002 to 0.015",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Normalization of corrected serum calcium by day 4 was superior in zoledronic acid (50 percent) compared to pamidronate (33 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Duration of complete response favored zoledronic acid: 32 to 43 vs. 18 days for pamidronate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Zoledronic acid 4 (and 8) mg IV three to four times weekly for 13 months (8 mg arm dropped secondary to excessive renal toxicity)",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td rowspan=\"4\">",
"        Pamidronate 90 mg IV three to four times weekly for 13 months",
"       </td>",
"       <td rowspan=\"4\">",
"        1648 patients with multiple myeloma or breast cancer patients with lytic disease",
"       </td>",
"       <td>",
"        The proportion of patients with at least one SRE was similar in all treatment groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Median time to the first SRE was approximately one year in each treatment group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zoledronic acid (4 mg) and pamidronate were equally well tolerated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The incidence of renal impairment: zoledronic acid 4 mg over 15 minute infusion was similar to that among patients treated with pamidronate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Zoledronic acid 4 (and 8) mg IV three to four times weekly for 24 months (8 mg arm dropped secondary to excessive renal toxicity)",
"        <sup>",
"         [6]",
"        </sup>",
"        (this report is a continuation of above study",
"        <sup>",
"         [5]",
"        </sup>",
"        )",
"       </td>",
"       <td rowspan=\"6\">",
"        Pamidronate 90 mg IV three to four times weekly for 24 months",
"       </td>",
"       <td rowspan=\"6\">",
"        1648 patients with multiple myeloma or breast cancer patients with lytic disease; 606 patients continued on extended study",
"       </td>",
"       <td class=\"sublist1_start\">",
"        At 25 months, 47 percent of patients on zoledronic acid and 51 percent of patients on pamidronate experienced an SRE other HCM, although results favored zoledronic acid for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Decreasing the percent of patients undergoing radiation therapy to bone (10 vs. 24 percent, p = 0.037)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Subset analysis demonstrated patients with MBC on endocrine therapy experienced an extended time to SRE (415 vs. 370 days, p = 0.047)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Skeletal morbidity rate was decreased 25 percent with zoledronic acid (1.04 events per year for 4 mg zoledronic acid vs. 1.39 events per year for pamidronate; p = 0.084), but in MBC on endocrine therapy, there were 0.83 SREs per year vs. 1.37 SREs per year, respectively; p = 0.039",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Multiple event analysis, including HCM, was in favor of zoledronic acid (95% CI), 0.719-0.983",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The presentation of the data from the long term follow up of this study, and the multiple events analysis has been criticized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Zoledronic acid 4 mg IV every four weeks for 12 months",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td rowspan=\"4\">",
"        Placebo IV every four weeks for 12 months",
"       </td>",
"       <td rowspan=\"4\">",
"        228 with at least one osteolytic metastases from breast cancer",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Results favored zoledronic acid for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Reducing SRE by 39 percent (p = 0.027). The SRE events per year was 0.63 for zoledronic acid vs. 1.10 events per year for placebo; p = 0.016",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        When including HCM into the SRE analysis, zoledronic acid provided a 40 percent relative reduction in the proportion of patients experiencing SREs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Multiple event demonstrated zoledronic acid HR 0.59; p = 0.019",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Zoledronic acid (4 mg) IV every&nbsp;four weeks",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"       <td rowspan=\"4\">",
"        Denosumab (120 mg) SQ every&nbsp;four weeks",
"       </td>",
"       <td rowspan=\"4\">",
"        2046 women, advanced breast cancer, with &ge;1 bone metastasis",
"       </td>",
"       <td class=\"sublist1_start\">",
"        Results favored denosumab for:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Significant delay in time to first on-study skeletal&nbsp;related event (HR 0.82, 95% CI, 0.71-0.95)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Significant decrease in the risk of developing multiple SREs (risk ratio 0.77, 95% CI, 0.66-0.89)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Signficant reduction in the mean skeletal morbidity rate (0.45 versus 0.58 events per patient per year)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HCM: hypercalcemia of malignancy; HR: hazard ratio; IV: intravenous; MBC: metastatic breast cancer; SRE: skeletal-related event.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Hortobagyi GN, et al. N Engl J Med 1996; 335:1785.",
"      </li>",
"      <li>",
"       Theriault R, et al. J Clin Oncol 1999; 17:846.",
"      </li>",
"      <li>",
"       Hortobagyi GN, et al. J Clin Oncol 1998; 16:2038.",
"      </li>",
"      <li>",
"       Major P, et al. J Clin Oncol 2001; 19:558.",
"      </li>",
"      <li>",
"       Rosen LS, et al. Cancer J 2001; 7:377.",
"      </li>",
"      <li>",
"       Rosen LS, et al. Cancer 2003; 98:1735.",
"      </li>",
"      <li>",
"       Kohno N, et al. J Clin Oncol 2005; 23:3314.",
"      </li>",
"      <li>",
"       Stopek AT, et al. J Clin Oncol 2010; 28:5132.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19118=[""].join("\n");
var outline_f18_42_19118=null;
var title_f18_42_19119="Chronic quad tendon tear";
var content_f18_42_19119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic tear of the quadriceps tendon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 334px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lateral radiograph of the knee demonstrates low position of the patella (arrow) secondary to chronic tear of the quadriceps tendon. A small suprapatellar effusion is also noted (arrowhead).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_42_19119=[""].join("\n");
var outline_f18_42_19119=null;
